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ENGLISH SUMMARY 
Antimicrobial treatment of infectious patients is increasingly complicated by 
frightening rates of antimicrobial resistance in infection-causing pathogens. The 
development of antimicrobial resistance is driven by the use and misuse of 
antimicrobials. Therefore, the choice of antimicrobial treatment should be 
appropriate to achieve the best outcome for both current and future patients. 
Hospitalised patients suspected of infection are often treated empirically with 
antimicrobials (i.e. before microbiological results on pathogen identity and 
antimicrobial susceptibility are available). Institutional antibiograms (ABG), which 
are aggregated local antimicrobial susceptibility test (AST) results, can be used as an 
indicator for the expected susceptibility to antimicrobials, when choosing empirical 
antimicrobial treatment. 
The aim of this project was to generate personalised ABGs, which predict patient-
specific antimicrobial susceptibility in the hospital setting. During the project, we 
focused on making the results of the research operational, by developing practical 
implementable applications. This thesis summarises the research and methods 
developed to generate personalised ABGs as a series of steps taken, starting with the 
institutional ABG.  
The first step was to generate ABGs representing patients with hospital-acquired 
infections and patients with community-acquired infections, respectively. Typically, 
AST results are available for a limited set of antimicrobials. When patient-specific 
AST results become available, and a treatment must be chosen, cross-resistance and 
cross-susceptibility for all available treatments must be considered. The next step was 
therefore to develop and validate a method which uses cross-susceptibility/resistance 
to adjust an ABG with respect to a patient’s AST results (Paper I). The next patient-
specific factor considered was the association between prior antimicrobial exposure 
and increased resistance at the patient level (Paper II). The results indicate to which 
degree the susceptibilities should be adjusted, for patients previously exposed to 
antimicrobials. A mathematical method was developed to modify the ABG with 
respect to a patient’s prior antimicrobial exposure. This method also served as an 
operationalisation of Paper II. The method was extended to modify the ABG with 
respect to both patient-specific prior exposure to antimicrobials and AST results 
(Patent pending). Future work involves the validation of this method. During the 
project the developed methods were implemented in an existing software solution for 
antimicrobial stewardship, Treat Steward. 
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DANSK RESUME 
Antimikrobiel behandling af infektioner er i stigende grad kompliceret af øget 
resistens hos de patogener, som forårsager infektioner. Udvikling af antimikrobiel 
resistens er drevet af brugen og misbrugen af antimikrobielle stoffer. Derfor bør 
valget af antimikrobiel behandling været særdeles velovervejet for at opnå det 
bedste resultat for både nuværende og fremtidige patienter. Indlagte patienter med 
tegn på infektion behandles oftest empirisk med antimikrobielle stoffer, før der 
forelægger mikrobiologiske resultater om patogen-identitet og antimikrobiel 
resistens. Institutionelle antibiogrammer (ABG), som er aggregerede lokale 
suceptibilitets-resultater, kan bruges som en indikator for den forventede 
susceptibilitet, når der vælges empirisk antimikrobiel behandling. 
Formålet med dette projekt var at skabe patientspecifikke ABG’er, der prædikterer 
antimikrobiel susceptibilitet hos indlagte patienter. I løbet af projektet, var der 
fokus på at gøre forskningsresultaterne operationelle, ved at udvikle praktiske 
implementerbare metoder. Denne afhandling opsummerer forskningen og 
metoderne udviklet til at generere patientspecifikke ABG’er. 
Det første skridt var at generere ABG’er til at repræsentere henholdsvis patienter 
med hospitalserhvervede infektioner og patienter med samfundserhvervede 
infektioner. AST resultater bliver typisk kun tilgængelige for et begrænset sæt af 
antimikrobielle stoffer. Når patientspecifikke AST resultater bliver tilgængelige, og 
skal vælges en behandling, bør kryds-susceptibilitet/resistens til alle tilgængelige 
behandlinger tages i betragtning. Det næste trin var derfor at udvikle og validere en 
metode, som anvender kryds-susceptibilitet/resistens til at justere et ABG i forhold 
til en patients AST resultater (Paper I). Den næste patient-specifikke faktor, der 
blev taget i betragtning var sammenhængen mellem tidligere antimikrobiel 
behandling og øget resistens på patientniveau (Paper II). Resultaterne indikerer i 
hvilket omfang susceptibiliteten skal justeres for patienter, som tidligere har 
modtaget antimikrobiel behandling. En matematisk metode blev udviklet til at 
modificere ABG’et i forhold til en patients tidligere antimikrobielle behandling. 
Denne metode fungerede også som en operationalisering af Paper II. Metoden blev 
udvidet til at justere ABG’et med hensyn til både en patientens tidligere behandling 
med antimikrobielle stoffer og patientens AST resultater (patentanmeldt). Det 
fremtidige arbejde involverer valideringen af denne metode. I projektet blev de 
udviklede metoder implementeret i TREAT Steward, som er en eksisterende 
softwareløsning til ”antimicrobial stewardship”. 
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PREFACE 
This PhD thesis includes both published and unpublished material. Chapter 2 
includes an abstract accepted for presentation at the 27th European Congress of 
Clinical Microbiology and Infectious Diseases (Vienna, April 2017). Material in the 
form of two published papers forms the basis of Chapter 3 and Chapter 4, 
respectively. Additionally, the thesis includes a mathematical method which is 
described in a patent application. The chapters based on published material are 
written as extended summaries, while those which present unpublished material are 
written in the form of chapters in a monograph. 
The work was carried out at the Center for Model-based Medical Decision Support, 
Department of Health Science and Technology at Aalborg University in Denmark. 
The PhD project contributes to the existing project of developing the decision support 
system for antimicrobial stewardship; Treat Steward, which had its origin in the same 
department. 
During the project, my focus has been on making the research operational, by 
developing practical applications, with the aim of shortening the way from research 
to an implemented solution available for clinicians and patients. 
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CHAPTER 1.  INTRODUCTION 
This chapter gives an introduction to the challenges that motivate this project, 
followed by an introduction to the scope of the project, describing the clinical area 
to which the project contributes. Finally, the research objectives addressed in each 
chapter are presented. 
Antimicrobial resistance is recognised by the WHO (World Health Organisation) as 
a major health threat of the 21st century. Resistance to the currently available 
antimicrobials currently claim upwards of 50,000 lives each year across Europe and 
the US (WHO, 2014).  
 “Without urgent, coordinated action, the world is heading towards a 
post-antibiotic era, in which common infections and minor injuries, which 
have been treatable for decades, can once again kill.”  
Dr Keiji Fukuda (WHO Assistant Director-General for Health Security) 
The emergence and spread of antimicrobial resistance is driven by the continued use 
and misuse of antimicrobials. The majority of human consumption of antimicrobials 
occurs in the community (outside hospitals). Nevertheless, antimicrobial 
consumption in hospitals is a main driver for the spread of antimicrobial-resistant 
bacteria responsible for healthcare-associated infections (ECDC, 2015). This thesis 
focuses on the use of antimicrobials in the hospital setting. It is in the hospital setting 
that the most extreme drug resistance has been found and the broadest-spectrum 
antimicrobials are being used (Doron and Davidson, 2011). The selection of resistant 
bacterial strains in individual hospitalised patients that is caused by antimicrobial 
exposure also have potential ecological implications in the community, through the 
spread of resistant strains (Timothy H. Dellit et al., 2007). Unfortunately, the 
extensive use of antimicrobials continues to increase; as an example the latest data 
on the overall antimicrobial consumption in the EU hospital sector (2010–2014) 
showed a significant increasing trend (ECDC, 2015). Moreover, an estimated 20-
50% of all antimicrobials prescribed in the hospital setting are either unnecessary or 
inappropriate (CDC, 2016; Timothy H. Dellit et al., 2007; Doron and Davidson, 
2011). 
The threat of resistance can be effectively mitigated either by the discovery of new 
antimicrobials or by a more appropriate use of antimicrobials. The already small and 
dwindling pipeline of drug candidates makes it unlikely that the rescue will come 
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from newly discovered drugs (WHO, 2014, 2011). The course of action, most likely 
to succeed, is to find ways of using the existing antimicrobials more prudently.  
Actions have been taken worldwide, where hospital based antimicrobial stewardship 
Programmes have been incorporated into hospital policies. The term antimicrobial 
stewardship covers coordinated interventions, to improve the quality of antimicrobial 
use. The primary goal is to optimise clinical outcomes and ensure cost-effectiveness 
of therapy, while minimizing unintended consequences of antimicrobial use, 
including toxic effects, selection of pathogenic organisms, and the emergence of 
antimicrobial resistance (CDC, 2016; Timothy H Dellit et al., 2007).  
The use of IT-based interventions, including decision support systems, have been 
shown to improve the appropriateness of antimicrobial prescribing in hospitals and 
present an exciting new prospect to target inappropriate antimicrobial prescribing 
(Baysari et al., 2016; Kullar et al., 2013; MacDougall and Polk, 2005). 
When a patient presents at a hospital and is suspected of having an infection, 
antimicrobials will be administered to the patient with the purpose of eradicating the 
microorganism causing the infection. Choosing an appropriate antimicrobial 
treatment is a complicated task where a number of factors must be considered. First, 
the clinician must make a reasonable guess on the diagnosis, the severity of the 
infection, and on the identity of the microorganism causing the disease (also known 
as a pathogen). Secondly, the clinician must make a reasonable guess on the 
susceptibility of the likely microorganisms(s) to the antimicrobials available for 
therapy, and based on these factors  choose an appropriate empirical antimicrobial 
treatment (Mandell et al., 2010; Schaechter et al., 2007). 
Empirical treatment is a medical term referring to the initiation of antimicrobial 
treatment prior to the determination of pathogen identity and antimicrobial 
susceptibility. Empirical treatment is often used when managing an infectious disease 
and can make the difference between cure and death for infected patients (Leibovici 
et al., 1998; Paul et al., 2010). The empirical treatment can be guided by a local 
institutional antibiogram (instABG) (Bax et al., 2001; Hindler and Stelling, 2007; 
Pakyz, 2007), also known as a “cumulative antibiogram report” (Hindler and Stelling, 
2007). An instABG is generated from statistics on the locally tested combinations of 
pathogens and antimicrobials and thereby reflects the resistance level in the given 
population.  From the instABG it can be read that, for example, the probability of E. 
coli being susceptible in vitro to cefuroxime is 71%.  
Before an empirical treatment is administered, samples will be taken from the patient, 
usually both a blood sample and a “local” sample from the suspected site of infection, 
for example a urine sample if the patient is suspected of a urinary tract infection. 
Within a day or two bacteria are successfully isolated from blood or local samples in 
approximately 30% of the patients (Paul et al., 2006). Once isolated, the bacteria are 
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tested for their in vitro susceptibility to a set of antimicrobials. The simplest and most 
widely used method for antimicrobial susceptibility testing (AST) is the disc 
diffusion test, where bacteria are seeded onto an agar plate and paper discs 
impregnated with antimicrobials are placed over the surface. After incubation 
susceptibility to antimicrobials appear by clear areas around the disk and resistance 
is indicated as bacterial growth up to the discs. The diameter of the zone of inhibition 
by diffusion of the antimicrobial on to the agar plate is used to determine the 
susceptibility of the bacteria to the set of tested antimicrobials. Quantitative methods 
are also used to provide estimate of a minimum inhibitory concentration (MIC), a 
value that can be used to determine whether an effective antimicrobial concentration 
is attainable in body fluids. The lowest concentration of the antimicrobial agent that 
prevents visible growth, usually after an 18- 24-hour incubation period, is the MIC 
(Mandell et al., 2010; Schaechter et al., 2007). 
The AST results from a bacterial isolate specify its susceptibility to each of the tested 
antimicrobials. The AST results can give reason to change the empirical treatment 
administered to the patient into a “final” treatment, where susceptibility to the 
antimicrobial treatment is confirmed by the AST. Due to the phenomenon of cross-
susceptibility/resistance an AST result showing susceptibility to an antimicrobial 
often implies susceptibility to similar antimicrobials. Likewise, an AST result 
showing resistance to an antimicrobial often implies resistance to similar 
antimicrobials. 
Factors specific to the patient suspected of infection must be considered to arrive at 
the optimal choice of antimicrobial treatment (Leibovici et al., 1999; Mandell et al., 
2010). In this project, we addressed the following patient specific factors related to 
antimicrobial susceptibility: 
1. Nosocomiality (NOSO): Patients with a Hospital-Acquired Infection (HAI) 
have a higher probability of being infected with resistant pathogens than 
patients with Community-Acquired Infections (CAI) (ECDC, 2017; Sanden 
et al., 2017). 
2. Prior Exposure (PE): Patients recently exposed to antimicrobials have 
higher probability of subsequent increased bacterial resistance (Bell et al., 
2014; Sanden et al., 2016).  
3. AST results: Typically, AST results becomes available for a limited set of 
antimicrobials. When patient-specific AST results become available, and a 
treatment must be chosen, cross-resistance and cross-susceptibility for the 
untested treatments must be considered (Andreassen et al., 2015; Leclercq 
et al., 2013). 
The aim of the project was to generate personalised ABGs, which predicts patient 
specific antimicrobial susceptibility in the hospital setting. During the project, we 
focused on making the research operational, by developing practical implementable 
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applications. The following chapters each present a step taken to generate 
personalised ABGs. These steps are shown on Figure 1.1. 
 
 
Figure 1.1: Flow diagram showing the steps taken to generate personalised ABGs, starting 
with an institutional ABG, which was modified first by nosocomiality (NOSO). The resulting 
ABG|NOSO was then modified by prior antimicrobial exposure (PE) resulting in an 
ABG|NOSO,PE and by AST results resulting in an ABG|NOSO,AST. The ABG|NOSO,PE and 
the ABG|NOSO,AST were then combined. Finally, in vivo susceptibility modifications were 
made in the already existing system, TREAT Steward. 
 
Chapter 2 provides of description of the work done to generate institutional ABGs 
accounting for nosocomiality. The first aim was to generate versions of the 
ABG|NOSO that represented community-acquired infections (ABG|CAI) and 
hospital-acquired infections (ABG|HAI), respectively. The second aim was to 
include evidence on cross-susceptibility/resistance in the ABGs, resulting in a 
crossABG|HAI and a crossABG|CAI. The crossABG was also a prerequisite for the 
approaches presented in Chapter 3 and Chapter 5. 
Chapter 3 is based primarily on Paper I. When AST results become available, it 
might give reason to adjust the expected susceptibility to antimicrobials for which 
susceptibility was not tested. The research objective was to develop and validate a 
method which uses cross-susceptibility/resistance to adjust an instABG with respect 
to AST results. The resulting personalised ABG is denoted ABG|AST. 
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Chapter 4 is based primarily on Paper II. Bacteria from patients recently exposed to 
antimicrobials have an increased probability of being resistant to antimicrobials 
compared to those not recently exposed to antimicrobials. To generate ABGs for 
these patients by adjusting an instABG, a quantification of the increased resistance 
was needed. The research objective was to quantify the effect of prior antimicrobial 
exposure at patient level.  
Chapter 5 describes a method developed with the purpose of modifying the instABG 
to account for a patient’s prior exposure (PE) to antimicrobials, where the resulting 
ABG is denoted ABG|PE. The chapter also serves as an operationalisation of Paper 
II. The content of this chapter is included in a patent application. 
Chapter 6 describes a method developed with the purpose of modifying the instABG 
to account for both PE and for AST results. The resulting ABG is denoted 
ABG|PE,AST. Like Chapter 5, the content of this chapter is also included in a patent 
application. 
Chapter 7 describes the implementation of the developed in vitro susceptibility 
modifications. The developed methods were implemented in TREAT Steward, a 
software solution for antimicrobial stewardship. The implementation is illustrated by 
going through a patient example.  
These chapters and the included objectives are steps towards generating personalised 
ABGs, serving as a better starting point for antimicrobial treatment than an instABG. 
Thereby the project seeks to contribute to patient specific antimicrobial stewardship. 
The main findings, scientific contributions are discussed in Chapter 8, which also 
gives a conclusion and addresses future work. 
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CHAPTER 2. INSTITUTIONAL ABGS 
To be able to generate personalised ABGs, we needed an instABG, which could be 
adjusted to patient specific factors. This chapter describes the approach used to 
generate an instABG from an isolate database, including the steps taken to ensure 
the quality of the isolate database. The chapter also describes how one of the patient 
specific factors, nosocomiality (NOSO), is taken into account by compiling two 
separate ABG|NOSO, one for community-acquired infections, the ABG|CAI and one 
for hospital-acquired infections, the ABG|HAI. Finally, the chapter describes the 
compilation of the cross-susceptibility and cross-resistance ABG, the crossABG of a 
given pathogen for pairs of antimicrobials. The crossABG is a prerequisite for the 
approaches presented in Chapter 3 and Chapter 5. Figure 2.1 shows the relation 
between the content of this chapter and the rest of the thesis. 
 
Figure 2.1: This chapter describes the first steps taken to generate personalised ABGs, 
resulting in ABG|NOSO. 
The instABG is generated from statistics on the locally tested combinations of 
pathogens and antimicrobials and thereby reflects the resistance level for the patients 
in the institution. In the context of generating personalised ABGs, the instABG serves 
as our prior knowledge, which can be adjusted by patient specific factors. To illustrate 
the process of generating an ABG|HAI and ABG|CAI and the corresponding 
crossABG|HAI and crossABG|CAI, we will use a microbiological isolate database 
from Rambam Health Care Campus in Israel as an example. The database was 
compiled for the period 2012 to 2015 as part of a hospital specific calibration of the 
software solution for antimicrobial stewardship, TREAT Steward (Treat Systems 
ApS). When the ABGs were generated, as traditionally recommended, solely on the 
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basis of institutional AST results, some complications and limitations arose, which 
will be addressed in the following. 
We divided the generation of an instABG into five steps, which will be described in 
the following sections: 
Step 1 – Quality-check of the isolate database: The purpose of the first step was to 
ensure the quality of the isolate database, which contained AST results for the 
pathogens isolated from patient samples at the hospital’s microbiological laboratory.  
Step 2 – Mapping reported species into pathogen groups: The reported species 
were mapped into pathogen groups, to decrease the risk of estimating susceptibilities 
on the basis of a few, or even zero observed cases. 
Step 3 - Hospital and community ABGs: The instABG was separated into an ABG 
representing hospital-acquired infections (ABG|HAI) and an ABG representing 
community-acquired infections (ABG|CAI). 
Step 4 – Filling in the gaps: For many entries, both in the ABG|HAI and the 
ABG|CAI, few or no susceptibility results were available. We explored how to 
include more evidence in the ABG|HAI and ABG|CAI to fill in the empty entries. 
Step 5 – Including cross-resistance in the ABG: The cross-susceptibility and cross-
resistance observed in the isolate database were included in a crossABG|HAI and a 
crossABG|CAI. A similar crossABG will be used in Chapter 3 and Chapter 5. 
 
2.1. QUALITY-CHECK OF THE ISOLATE DATABASE 
The compiled isolate database from Rambam contained all AST results from in vitro 
isolated pathogens from all sample types (e.g. blood, urine, sputum). The database 
contained 44,557 patient- and episode-unique isolates. Examples are presented in 
Table 2.1. Each isolate was associated with information about: 
 Isolate ID 
 Patient ID (anonymised) 
 Patient age 
 Admission date of the patient 
 Sample date (when the sample was taken) 
 Sample type (blood or other) 
 Species name  
 AST results (susceptible=S, resistant=R or intermediate=I) 
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200150001 1572832 77 12/31/2011 1/1/2012 
Enterococcus 
faecalis 
        
200150004 1395133 24 1/1/2015 1/1/2015 Escherichia coli S  R   S S S 
200150010 1407741 76 12/21/2013 12/21/2013 
Klebsiella 
pneumoniae ssp  
R  R   R R R 
200150011 1604350 47 12/31/2014 12/31/2014 
Enterobacter 
cloacae 
S     S S R 
Table 2.1: A segment of the data contained in the isolate database from Rambam. 
Isolates were selected for further analysis provided: 
1. The first 6 columns containing Isolate ID, Patient ID, Patient age, Admission 
date, Sample date and Pathogen name were all filled in, 
2. The patient’s age was over 18 years, 
3. Admission date was before the Sample date, and  
4. The isolate was not a duplicate. 
 
Two isolates were defined as duplicates if the isolates were from the same patient, 
had the same species name and the sample dates were separated by less than 30 days. 
To decide which one of the duplicates to be considered for deletion, a number of 
checks were performed. The duplicate to be deleted was identified by being: 
 The isolate with the lowest number of AST results, or 
 If the isolates had the same number of AST results: The least resistant isolate 
(fewest number of AST results = R), or 
  If the two samples have identical AST results: The newest isolate. 
A list of isolates with issues was constructed, i.e. a list of all isolates not satisfying 
one or more of the above criteria (Table 2.2). The list was used as a review tool where 
the reviewer could enter Yes or No in the “Delete isolate?” column and also enter a 
comment.  
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Issue 
ID 
Isolate ID Mistakes description Delete 
isolate? 
Comment 
1 201226091 Duplicate of isolate: 201225342 Yes   
2 201208437 Duplicate of isolate: 201208305 Yes   
3 201208305 Duplicate of isolate: 201213276 Yes   
4 201208437 Duplicate of isolate: 201213276 Yes   
Table 2.2: A segment of a list of isolates with identified issues. 
In total, we identified 10,129 issues that were added to the list. A review by a clinical 
expert from the institution had the purpose of identifying which issues should be 
deleted from the isolate database, and whether additional data could be provided in 
cases of missing data. After the review, all 10,129 isolates were deleted and the 
remaining 34,427 were selected for further analysis.  
 
2.2. MAPPING SPECIES INTO PATHOGEN GROUPS  
In the microbiological laboratory, the name of the identified species is reported for 
each isolate. Even though an isolate database may contain several thousand isolates 
like the Rambam database, some of the species do not occur frequently. As a 
consequence, the susceptibility for some pathogen/antimicrobial combinations must 
be decided on the basis of a few, or even zero observed cases. Since susceptibilities 
change over time, the problem cannot be solved by including susceptibility data for 
a longer period of time. It is recommended that clinical microbiology laboratories 
generate local ABGs with pathogen-specific susceptibility data annually, to optimise 
recommendations for empirical therapy (Mandell et al., 2010). Susceptibility data 
older than three years should definitely be used with caution. To get higher isolate 
counts, it may be useful to construct an ABG|HAI and an ABG|CAI for groups of 
pathogens, where each pathogen group may contain one or more species. If the 
groups are carefully defined the loss of species resolution caused by the grouping 
may be more than compensated for by the reduction in statistical noise caused by the 
higher counts, thus providing an overall improved accuracy of the estimates of 
susceptibility (Andreassen et al., 2009). 
In the isolate database from Rambam, we found 285 different species names. The 
reporting of species names was not standardised, and therefore there the 285 different 
names may not truly reflect 285 different types of species. Table 2.3 shows the 
mapping of species into pathogen groups for the Rambam database, where the 
reported species names were mapped into 27 pathogen groups. The mapping was 
approved by a local expert. Even though the grouping of species provided higher 
isolate counts, some groups were still represented by sparse susceptibility data with 
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counts smaller than 20 (Campylobacter, HACEK, Listeria, Meningococcus, 
Moraxella, and Streptococcus group D). 
Pathogen group Species reported from institutional laboratory 
Acinetobacter  
(N = 1278) 
Acinetobacter baumannii Acinetobacter radioresistens 
Acinetobacter calcoaceticus Acinetobacter spp 
Acinetobacter haemolyticus Acinetobacter ursingii 
Acinetobacter johnsonii Nocardia brasiliensis 
Acinetobacter junii Nocardia spp 
Acinetobacter lwoffii Streptomyces species 
 
Campylobacter 
(N = 15) 
Campylobacter fetus Campylobacter spp 
Campylobacter jejuni  
 
Candida 
(N = 161) 
Aspergillus flavus Candida parapsilosis 
Aspergillus fumigatus Candida pelliculosa 
Aspergillus Niger Candida species,not albicans 
Aspergillus terreus Candida tropicalis 
Candida albicans Fusarium spp 
Candida dubliniensis Mould fungus 
Candida glabrata Saccharomyces cerevisiae 
Candida krusei  
 
Citrobacter 
(N = 788) 
Citrobacter amalonaticus Citrobacter koseri (C. diversus) 
Citrobacter braakii Citrobacter sedlakii 
Citrobacter farmeri Citrobacter spp 
Citrobacter freundii Citrobacter youngae 
Citrobacter koseri  
 
Escherichia coli 
(N = 8563) 
Escherichia coli Escherichia hermannii 
Escherichia fergusonii  
 
Enterobacter 
(N = 1199) 
Enterobacter aerogenes Enterobacter cloacae 
Enterobacter amnigenus Enterobacter gergoviae 
Enterobacter asburiae Enterobacter species 
 
Enterococcus 
(N = 4348) 
Enterococcus avium Enterococcus gallinarum 
Enterococcus casseliflavus Enterococcus hirae 
Enterococcus durans Enterococcus raffinosus 
Enterococcus faecalis Enterococcus spp 
Enterococcus faecium  
 
Gram Negative 
Anaerobe 
(N = 213) 
Anaerobic gram negative rods Fusobacterium mortiferum  
Anaerobic gram positive rod Fusobacterium nucleatum  
Bacteroidas ovatus Fusobacterium spp  
Bacteroides caccae Prevotella bivia  
Bacteroides distasonis Prevotella intermedia  
Bacteroides fragilis Prevotella melaninogenica  
Bacteroides spp Prevotella oralis  
Bacteroides stercoris Prevotella oris  
Bacteroides thetaiotaomicron 
Prevotella species (non-pigmented 
group) 
 
Bacteroides uniformis 
Prevotella species (pigmented 
group) 
 
Bacteroides vulgatus Veillonella parvula  
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Delftia acidovorans Veillonella spp  
 
Gram Positive 
Anaerobe 
(N = 95) 
Actinomyces meyeri Clostridium spp 
Actinomyces naeslundii Clostridium subterminale 
Actinomyces spp Eubacterium lentum 
Anaerobic gram positive coccus Eubacterium spp 
Arcanobacterium haemolyticum Peptococcus sp. 
Clospridium spp Peptostreptococcus anaerobius 
Clostridium barati 
Peptostreptococcus 
asaccharolyticus 
Clostridium clostridiiforme Peptostreptococcus micros 
Clostridium paraputrificum Peptostreptococcus sp. 
Clostridium perfringens Propionibacterium acnes 
Clostridium septicum Propionibacterium species 
Clostridium sordellii Rothia mucilaginosa 
 
Gram Positive Rods 
(N = 64) 
Bacillus species Corynebacterium species 
Bacillus subtilis (globigii) Corynebacterium stariatum 
Corynebacterium amycolatum Corynebacterium urealyticum 
Corynebacterium jeikeium group Cryptococcus neoformans 
Corynebacterium minutissimum Erysipelothrix rhusiopathiae 
Corynebacterium 
pseudodiphteriticum 
Gram positive bacilli 
 
HACEK 
(N = 3) 
Eikenella corrodens 
 
Haemophilus 
(N = 329) 
+Haemophilus influenza beta lact Haemophilus influenzae 
-Haemophilus influenza beta lact Haemophilus parainfluenzae 
Haemophilus influenza invasive Haemophilus spp 
 
Klebsiella 
(N = 4469) 
Klebsiella oxytoca 
Klebsiella pneumoniae ssp 
pneumoniae 
Klebsiella oxytoca/(Raoultella 
planticola/terrigena) 
Klebsiella pneumoniae ssp 
pneumoniae/(R.planticola/terrig.) 
Klebsiella pneumoniae Klebsiella spp 
Klebsiella pneumoniae ssp 
ozaenae 
 
 
Listeria 
(N = 10) 
 
Listeria monocytogenes Listeria species 
 
Meningococcus 
(N = 1) 
Neisseria meningitidis 
 
Moraxella 
(N = 10) 
Moraxella group Moraxella osloensis 
 
Other Gram Negative 
(N = 943) 
Achromobacter xylosoxidans ssp 
denitrificans Kluyvera cryocrescens 
Achromobacter xylosoxidans ssp 
xylosoxidans Kluyvera species 
Aeromonas hydrophila/caviae Neisseria cinerea 
Aeromonas salmonicida Neisseria gonorrhoeae 
Aeromonas sobria Neisseria spp 
Aeromonas spp 
Nonfermenting Gram-Negative 
Bacillus 
Aeromonas veronii biovar veronii Ochrobactrum anthropi 
Alcaligenes faecalis ssp faecalis 
Pantoea agglomerans (formerly 
enterobacter agglomerans) 
Bordetella bronchiseptica Pantoea spp 
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Branhamella catarrhalis Pasteurella multocida 
Brevundimonas diminuta Pasteurella pneumotropica 
Brevundimonas 
diminuta/vesicularis Pasteurella spp 
Brucella melitensis Prevotella disiens 
Brucella melitensis complement Rahnella aquatilis 
Burkholderia cepacia Raoultella ornithinolytica 
Burkholderia cepacia group Raoultella planticola 
Burkholderia gladioli Rhizobium radiobacter 
Cedecea davisae Serratia ficaria 
Chryseobacterium gleum Serratia fonticola 
Chryseobacterium indologenes Serratia liquefaciens 
Chryseobacterium 
meningosepticum Serratia liquefaciens group 
Comamonas testosteroni Serratia marcescens 
Ewingella americana Serratia odorifera 
Finegoldia magna Serratia plymuthica 
Gardnerella vaginalis Serratia rubidaea 
Globicatella sanguinis Serratia species 
Gram negative bacilli Shewanella putrefaciens group 
Gram negative coccobacilli Sphingobacterium spiritivorum 
Granulicatella adiacens Sphingobacterium thalpophilum 
Granulicatella elegans Sphingomonas paucimobilis 
Hafnia alvei Stenotrophomonas maltophilia 
 
Pneumococcus 
(N = 215) 
Streptococcus pneumoniae 
 
Proteus 
(N = 2818) 
Morganella morganii Proteus vulgaris group 
Morganella morganii ssp morganii 
Proteus vulgaris group/Proteus 
penneri 
Morganella morganii ssp sibonii Providencia alcalifaciens 
Proteus mirabilis Providencia rettgeri 
Proteus penneri Providencia species 
Proteus species Providencia stuartii 
 
Pseudomonas 
(N = 215) 
Pseudomonas aeruginosa Pseudomonas pseudoalcaligenes 
Pseudomonas fluorescens Pseudomonas putida 
Pseudomonas luteola Pseudomonas spp 
Pseudomonas mendocina Pseudomonas stutzeri 
Pseudomonas oryzihabitans  
 
Salmonella non typhi 
(N = 44) 
Salmonella enteritidis Salmonella spp 
Salmonella group  
 
Staphylococcus -
Coagulase negative 
(N = 1437) 
 
Coagulase negative 
Staphylococcus 
Staphylococcus hominis ssp 
hominis 
Micrococcus luteus / lylae Staphylococcus hyicus 
Micrococcus species Staphylococcus intermedius 
Staphylococcus auricularis Staphylococcus lentus 
Staphylococcus capitis Staphylococcus lugdunensis 
Staphylococcus caprae Staphylococcus saccharolyticus 
Staphylococcus chromogenes Staphylococcus saprophyticus 
Staphylococcus cohnii ssp cohnii Staphylococcus schleiferi 
Staphylococcus cohnii ssp 
urealyticum 
Staphylococcus sciuri 
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Staphylococcus epidermidis Staphylococcus simulans 
Staphylococcus haemolyticus Staphylococcus warneri 
Staphylococcus hominis Staphylococcus xylosus 
 
Staphylococcus -
Coagulase positive 
(N = 2973) 
Gram positive cocci consistent 
with Staphylococcus 
Staphylococcus aureus 
 
Streptococcus group A 
(N=24) 
 Streptococcus pyogenes (group A) 
Streptococcus group B 
(N = 434) 
Streptococcus agalactiae (Group 
B) 
Streptococcus group B 
 
Streptococcus group D 
(N = 16) 
Streptococcus alactolyticus 
Streptococcus gallolyticus ssp 
gallolyticus 
Streptococcus gallolyticus Streptococcus gordonii 
 
Streptococcus viridans 
(N = 259) 
Alpha haemolytic Streptococcus Streptococcus pluranimalium 
Gemella morbillorum  
Streptococcus parasanguinis Streptococcus salivarius 
Streptococcus infantarius ssp coli Streptococcus sanguis 
Streptococcus mitis/oralis/  Streptococcus spp 
Streptococcus mitis/Streptococcus 
oralis 
Streptococcus vestibularis 
Streptococcus mutans Streptococcus viridans group 
Streptococcus pasteurianus  
 
Streptococcus  
(N = 137) 
Aerococcus viridans  
Streptococcus dysgalactiae ssp 
equisimilis  
Str.dys.dysgalactiae/Str.dys.equisi
milis 
Streptococcus group C 
Streptococcus anginosus Streptococcus group F 
Streptococcus canis Streptococcus group G 
Streptococcus constellatus Streptococcus intermedius 
Streptococcus constellatus 
(viridans strep) Streptococcus thermophilus 
Streptococcus constellatus ssp 
pharyngis Streptococcus thoraltensis  
Streptococcus dysgalactiae ssp 
dysgalactiae 
 
 
Table 2.3: The mapping of species into pathogen groups for the Rambam database. 
 
As an example, Table 2.4 shows the last pathogen group from Table 2.3, 
streptococcus. It can be seen, that only 2 out of 15 reported species were isolated 
more than 20 times. For the majority of the reported species in this group, the small 
number of isolates are not useful to compile a species-specific susceptibility profile 
in an instABG. When segregating the isolates into those representing HAIs and CAIs, 
the number of isolates in each group are further reduced. In section 2.4 we explore 
how to include more evidence in the ABG|HAI and ABG|CAI, than what can be 
achieved by using statistics on institutional AST results. 
  
CHAPTER 2. INSTITUTIONAL ABGS 
 
30 
The streptococcus pathogen group N 
Aerococcus viridans 8 
Str.dys.dysgalactiae/Str.dys.equisimilis 4 
Streptococcus anginosus 56 
Streptococcus canis 1 
Streptococcus constellatus 9 
Streptococcus constellatus (viridans strep) 2 
Streptococcus constellatus ssp pharyngis 5 
Streptococcus dysgalactiae ssp dysgalactiae 2 
Streptococcus dysgalactiae ssp equisimilis 25 
Streptococcus group C 1 
Streptococcus group F 2 
Streptococcus group G 3 
Streptococcus intermedius 15 
Streptococcus thermophilus 3 
Streptococcus thoraltensis 1 
Total number of streptococcus isolates 137 
Table 2.4: The number of isolates in the streptococcus pathogen group. 
 
2.3. HOSPITAL AND COMMUNITY ABGS 
One of the patient specific factors that the ABG can be adjusted for is nosocomiality, 
i.e. whether the infection is hospital-acquired or community-acquired. The high rates 
of antimicrobial resistance in hospitals has been associated with high rates of 
antimicrobial use (Doron and Davidson, 2011). Patients with hospital-acquired 
infections therefore have a higher probability of being infected with resistant 
pathogens than patients that have acquired an infection elsewhere. This gives reason 
to compile an ABG|HAI for hospital-acquired infections (HAI) and an ABG|CAI for 
community-acquired infections (CAI). The effect of higher resistance in HAIs has 
been shown to be sufficiently expressed in infections acquired after at least 7 days in 
hospital, to be used to generate hospital specific ABGs (Dickstein et al., 2016). 
Throughout the thesis, we will use three versions of the instABG, which were defined 
as follows: 
The ABG|CAI included isolates from samples drawn before a patient had spent 7 
days in hospital. Thereby the ABG|CAI mainly represents patients, who had 
community-acquired infections, but isolates from patients coming from other 
healthcare facilities than the hospital (e.g. nursing home) could also be included. 
The ABG|HAI included isolates from samples drawn after a patient had spent 7 days 
in hospital. The ABG|HAI thereby represents patients, who had hospital-acquired 
infections.  
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The instABG included the total patient population represented in the isolate database 
from the microbiological laboratory. The instABG thereby included both the 
ABG|HAI and the ABG|CAI. 
Table 2.5 shows the antimicrobial specific susceptibilities for biggest pathogen 
group, E. coli, in the three versions of the ABG. It can be seen, for example, that the 
probability of an E. coli isolate being susceptible to cefuroxime is 71.2% in CAIs and 
49.6% in HAIs.  
Pathogen: E. coli Probability of susceptibility 
Antimicrobial instABG ABG|CAI ABG|HAI 
Ampicillin 25.2% 26.6% 13.4% 
Piperacillin 31.6% 32.4% 25.0% 
Amoxicillin-clavulanate 78.3% 80.0% 63.0% 
Piperacillin-tazobactam 92.9% 93.6% 86.8% 
Cefazolin 50.0% 53.2% 28.6% 
Cefuroxime 68.9% 71.2% 49.6% 
Ceftazidime 72.7% 74.8% 55.1% 
Ceftriaxone 72.8% 74.9% 55.3% 
Meropenem 99.7% 99.8% 99.0% 
Ertapenem 99.7% 99.8% 99.1% 
Imipenem-cilastatin 99.7% 99.8% 99.4% 
Aztreonam 41.5% 36.2% 55.6% 
Doxycycline 45.4% 47.3% 30.0% 
Gentamicin 81.1% 82.5% 69.1% 
Amikacin 99.5% 99.7% 98.3% 
Ofloxacin 57.2% 58.1% 47.3% 
Ciprofloxacin 57.5% 59.3% 41.9% 
Nitrofurantoin 95.8% 95.8% 96.4% 
Fosfomycin 99.1% 99.1% 98.6% 
Sulfa-trimethoprim 54.2% 55.7% 41.5% 
Chloramphenicol 90.3% 89.3% 95.7% 
Table 2.5:  Probability of susceptibility in E. coli isolates. 
We compared the susceptibility levels in the ABG|HAI and the ABG|CAI (Sanden et 
al., 2017). The differences in resistance levels were calculated as odds ratios (ORs) 
with 95% confidence intervals (CI) for resistance. The results presented in the 
following are mainly based on a conference abstract (ECCMID 2017)(Sanden et al., 
2017). 
Figure 2.2 shows the difference in the susceptibility data from HAI and CAI for the 
pathogen group with the highest number of AST results, E. coli (NAST = 113,791). As 
expected, E. coli showed significantly higher resistance to most antimicrobials (16 
out of the 21 antimicrobials) in HAIs compared to resistance in CAIs. This included 
significantly higher resistance in HAIs for all penicillins (ORs: 2.2-2.4), 
cephalosporins (ORs: 2.4-2.8), aminoglycosides (ORs: 2.1-5.1), and quinolones 
(ORs: 1.5-2.0). 
CHAPTER 2. INSTITUTIONAL ABGS 
 
32 
 
 
Figure 2.2: ORs for higher resistance in E. coli isolates from patients with HAI compared to 
CAI. Each antimicrobial is presented with [Number of AST results] and the percentage of 
susceptible isolates from CAI. 
Table 2.6 shows the nine pathogen groups with the highest number of AST results 
across all tested antimicrobials in the database. These pathogen groups represent a 
sum of 320,010 AST results or 92% of all AST results. All pathogen groups had 
significant ORs for increased resistance in HAI isolates ranging from 1.3 to 4.0. The 
largest difference in resistance between bacteria isolated from HAIs and bacteria 
isolated CAIs was observed for Acinetobacter, which is a typical pathogen for HAIs, 
but not in the community.  
  
CHAPTER 2. INSTITUTIONAL ABGS 
 
33 
Pathogen group NAST (%HAI) OR (95% CI) 
Acinetobacter 11,031 (51%) 4.0 (3.7-4.3) 
Staph. coag. pos. 25,620 (24%) 2.6 (2.4-2.8) 
Staph. coag. neg. 11,852 (20%) 2.1 (1.9-2.3) 
Klebsiella 58,499 (25%) 2.1 (2.0-2.2) 
Enterococcus 17,292 (19%) 1.8 (1.7-2.0) 
E. coli 113,791 (10%) 1.7 (1.7-1.8) 
Pseudomonas 30,500 (39%) 1.6 (1.5-1.7) 
Proteus 36,588 (24%) 1.5 (1.4-1.6) 
Enterobacter 14,837 (23%) 1.3 (1.2-1.4) 
All pathogen groups 343,761 (21%) 1.94 (1.87-1.94) 
Gram- pathogen groups 286,098 (21%) 1.87 (1.84-1.91) 
Gram+ pathogen groups 56,877 (21%) 2.24 (2.14-2.34) 
Table 2.6: ORs for higher resistance in HAI compared to CAI. 
As expected we observed a significant difference in resistance level in the 
susceptibilities from the ABG|HAI and the ABG|CAI. The results emphasise the 
importance of personalising the instABG with respect to HAI and CAI. 
2.4. FILLING IN THE GAPS IN THE ABGS  
The ABG|HAI and ABG|CAI from Rambam each included 27 pathogen groups and 
55 antimicrobials, giving a total number of 27*55 = 1485 entries in each of these 
ABGs. Table 2.7 shows a segment of the AST results used in the ABG|HAI. Many 
of the entries remained empty or only contained a few results (coloured red). By using 
the statistics from pathogen/antimicrobial combinations with >10 AST results it was 
possible to fill in 213 (15%) of the 1485 entries in the ABG|HAI and 265 (18%) of 
the entries in the ABG|CAI. 
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HAI statistics   Pathogen 
Antimicrobial  A
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Penicillin S 0 0 8 
J01CE01 R 0 0 0 
Cloxacillin S 0 0 0 
J01CF02 R 0 0 0 
Oxacillin S 0 0 0 
J01CF04 R 0 0 0 
Ampicillin-sulbactam S 267 0 0 
J01CR01 R 257 0 0 
Amoxicillin-clavulanate S 0 427 0 
J01CR02 R 0 251 0 
Piperacillin-tazobactam S 52 488 0 
J01CR05 R 567 74 0 
Cefalexin S 0 0 0 
J01DB01 R 0 0 0 
Cefazolin S 0 20 0 
J01DB04 R 0 50 0 
Cefuroxime S 0 412 0 
J01DC02 R 0 418 0 
Table 2.7: A segment of the AST results used in the ABG|HAI. 
For the ABG to be used as a guidance for the choice of antimicrobial therapy both 
for clinicians and for decision support systems, all entries must be filled in. Although 
the susceptibility is usually tested to antimicrobials which are likely to be chosen for 
therapy, it may be necessary to use an antimicrobial, for which few or no 
susceptibility results are available in the ABG|HAI or ABG|CAI.  
 INCLUDING PRIOR DISTRIBUTIONS 
To fill in the empty entries in the ABG we explored how to include more evidence in 
the ABG|HAI and ABG|CAI, than what can be achieved by using statistics on 
institutional AST results. This additional evidence may, in the Bayesian tradition, be 
considered prior information, i.e. prior to the statistical processing of the institutional 
AST results. This evidence can be expressed as (prior) probability distributions, for 
example based on:  
 Susceptibility data from another period of time 
 Susceptibility data from another institution 
 Opinions from clinical experts   
 Observations from the literature 
The probabilities derived from these sources are expressed as Dirichlet counts.  For 
example, the prior opinion derived from one of these sources may be that the 
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probability of susceptibility of E. coli to cefuroxime is 80%. This may be expressed 
as 8 imaginary “Dirichlet observations” in the isolate database of susceptibility and 
2 observations of resistance. A convenient property of this way of expressing prior 
opinions is that the Bayesian posterior probability is very simple to calculate. The 
Dirichlet observations are simply added to any real observations in the isolate 
database (Spiegelhalter et al., 1993). For example, if the isolate database contains 100 
observations of the susceptibility of E. coli to cefuroxime, 71 (71%) showing 
susceptibility and 29 (29%) showing resistance then the posterior probability of 
susceptibility would be (8 + 71) / (8+ 71 + 2 + 29) = 72% (Table 2.8). This is close 
to the 71% observed in the isolate database. Had the number of Dirichlet observations 
been 1000, 800 observation of susceptibility and 200 of resistance, then the resulting 
posterior would have been 79%. This is close to the prior opinion and this example 
illustrates that the number of imaginary Dirichlet observation can be used to indicate 
the strength of the prior opinion; A large Dirichlet count (1000) indicating a strong 
prior opinion and a small Dirichlet count (10) indicating a weak prior opinion.  
Pathogen: E. coli 
Antimicrobial A
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Weak prior opinion 
Cefuroxime S 71 8 
72% 
J01DC02 R 29 2 
Strong prior opinion 
Cefuroxime S 71 800 
79% 
J01DC02 R 29 200 
Table 2.8: An example of the use of Dirichlet observations. 
To generate an ABG|HAI and ABG|CAI for Rambam, we included the following 
prior distributions: 
Susceptibility data from another institution: We included an instABG generated 
at another Israeli hospital. The instABG was compiled at Beilinson Hospital at Rabin 
Medical Center and contained susceptibility data from the period 2011-2014. A 
segment of the susceptibility data used from this instABG is shown in the column 
“Rab2014” in Table 2.9. Counts from the Rab2014 instABG were downscaled to give 
a sum of 10. In this way, the contribution of these counts depends on the number of 
AST results in the currently assessed database (Ram2015). The higher the counts 
from the new isolate database, the smaller the weight from the prior results on the 
aggregated probability of susceptibility (“Coverage”).  
Opinions from clinical experts: We included expert opinions on the level of 
susceptibility suggested by clinical experts at Beilinson Hospital (Rabin Medical 
Center) in 2014. These opinions were expressed as statistical counts and examples 
are shown in the column “Prior opinion” in Table 2.9. 
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Observations from the literature: EUCAST (The European Committee on 
Antimicrobial Susceptibility Testing) has designed a set of rules on intrinsic 
resistance and exceptional phenotypes (EUCAST, 2016). EUCAST expert rules on 
intrinsic resistance were expressed as S=0 and R=1000, giving a coverage of 0%.  
EUCAST expert rules on resistance of exceptional phenotypes were expressed as S 
=1000 and R=0, giving a coverage of 100%. These counts were included in the 
column “Prior opinion” in Table 2.9. 
Table 2.9 shows a segment of these distributions for E. coli, alongside the statistics 
from the current isolate database, all expressed as statistical counts on susceptibility 
versus resistance. We will come back to the column “New opinion” in the next 
section. 
HAI statistics  Pathogen: E. coli 
Antimicrobial  A
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Ampicillin-sulbactam S 0 4.8 39.8  
41% 
J01CR01 R 0 5.2 60.2  
Amoxicillin-clavulanate S 427 6.9 45.1  
61% 
J01CR02 R 251 3.1 54.9  
Piperacillin-tazobactam S 488 9.6 82.5  
86% 
J01CR05 R 74 0.4 17.5  
Cefalexin S 0 6.4 0  
1% 
J01DB01 R 0 3.7 1000  
Cefazolin S 20 0 20  
24% 
J01DB04 R 50 0 80  
Cefuroxime S 412 6.4 51.7  
50% 
J01DC02 R 418 3.6 48.3  
Table 2.9: A segment of the statistical distributions for E. coli in HAIs. 
 REVIEW AND NEW OPINIONS 
Now with the distributions available, the next step towards a final ABG was to get 
the susceptibility data, representing our current posterior belief, reviewed by a 
clinical expert from the institution. This was done to get input about local 
susceptibilities, which were not reflected in the available statistical counts. The 
column “New opinion” was used to handle this process where the reviewer could 
enter opinions expressed as statistical counts (Table 2.10).  
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HAI statistics   Pathogen: E. coli 
Antimicrobial A
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Ampicillin-sulbactam S 0 4.8 39.8 428 
60% 
J01CR01 R 0 5.2 60.2 252 
Amoxicillin-clavulanate S 427 6.9 45.1 427 
62% 
J01CR02 R 251 3.1 54.9 251 
Piperacillin-tazobactam S 488 9.6 82.5 488 
87% 
J01CR05 R 74 0.4 17.5 74 
Cefalexin S 0 6.4 0 20 
2% 
J01DB01 R 0 3.7 0 51 
Cefazolin S 20 0 20 20 
25% 
J01DB04 R 50 0 80 50 
Cefuroxime S 412 6.4 51.7 412 
50% 
J01DC02 R 418 3.6 48.3 418 
Table 2.10: A segment of the review tool with statistical distributions for E. coli in HAIs. 
As a helping tool to draw the reviewer’s attention to cases with divergent statistics, 
we highlighted the cells: 
 Green shading indicated a significant difference in susceptibility counts 
between the RAM2015 and the RAB2014 statistics.  
 Yellow shading indicated a difference between the prior opinion and the 
total counts from the RAM2015 and the RAB2014 statistics. 
 Red shading indicated if new opinions deviated significantly from the sum 
of the other three columns. 
The resulting column “Coverage” in Table 2.10 now shows a segment of the final 
coverages used in the ABG|HAI for E. coli. The coverage was calculated as the sum 
of the three distributions and expressed as the probability of susceptibility. For 
example, the probability of an E. coli isolate being susceptible to ampicillin-
sulbactam is (4.8 + 39.8 + 428) / (4.8 + 39.8 + 428 + 5.2 + 60.2 + 252) = 60%.  
 
2.5. INCLUDING CROSS-SUSCEPTIBILITY/RESISTANCE IN THE 
ABG 
Susceptibility to an antimicrobial often implies susceptibility to similar 
antimicrobials and resistance to an antimicrobial often implies resistance to similar 
antimicrobials. When patient specific AST results become available, we can use 
knowledge on cross-susceptibility/resistance as an indicator for whether to expect 
susceptibility or resistance to antimicrobials for which no AST results are available. 
CHAPTER 2. INSTITUTIONAL ABGS 
 
38 
This activity is known as interpretative reading of the ABG (Courvalin, 1996; 
Leclercq et al., 2013) In Chapter 3 and Chapter 5, we explore approaches of 
interpretative reading. In these approaches, we used a crossAGB, which contained 
statistics on cross-susceptibility/resistance between pairs of antimicrobials for each 
pathogen group.  
Table 2.11 shows an example of the statistical data on cross-susceptibility/resistance 
that can be obtained from an isolate database, in this case on E. coli isolates in HAIs 
from Rambam 2012-2015. Some of the antimicrobials and antimicrobial 
combinations have zero AST results (“0”), and thereby no data which can be used to 
calculate the level of cross-susceptibility/resistance. 
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Antimicrobial AST statistics S R S R S R 
Ampicillin-sulbactam S 0 0 0 0 0 0 0 
J01CR01 R 0 0 0 0 0 0 0 
Amoxicillin-clavulanate S 427 317 85 0 0 335 83 
J01CR02 R 251 28 201 0 0 52 188 
Piperacillin-tazobactam S 488 254 187 0 0 295 177 
J01CR05 R 74 13 52 0 0 25 46 
Table 2.11: An example of the data on cross-susceptibility/resistance that can be obtained 
from an isolate database. 
From the data given in Table 2.11 we can for example calculate the probability of 
susceptibility to amoxicillin-clavulanate, which is denoted P(amoCl) as: 
P(amoCl) = 427 / (427+251) = 0.63 = 63%.  
The conditional probability of susceptibility to amoCl given susceptibility to 
cefuroxime (cefur) is denoted P(amoCl|cefur) and is calculated as: 
P(amoCl|cefur) = 317/ (317+28) = 0.92 = 92%  
The OR for increased susceptibility to amoCl given susceptibility to cefur is 
calculated as: 
𝑂𝑅𝑎𝑚𝑜𝐶𝑙|𝑐𝑒𝑓𝑢𝑟 =
𝑂𝐷𝑎𝑚𝑜𝐶𝑙|𝑐𝑒𝑓𝑢𝑟
𝑂𝐷𝑎𝑚𝑜𝐶𝑙
=  
𝑃(𝑎𝑚𝑜𝐶𝑙|𝑐𝑒𝑓𝑢𝑟)
1−𝑃(𝑎𝑚𝑜𝐶𝑙|𝑐𝑒𝑓𝑢𝑟)
1−𝑃(𝑎𝑚𝑜𝐶𝑙)
𝑃(𝑎𝑚𝑜𝐶𝑙)
=
0.92
0.08
0.37
0.63
= 6.7  
 
(These probabilities can be found in Table 2.12) 
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If we then consider susceptibility to amoCl given resistance to cefur, denoted 
P(amoCl|¬cefur), only 85 (30%) out of 286 isolates were susceptible to amoCl, with 
the corresponding OR = 0.2. In this example, an AST result on cefuroxime would be 
a useful indicator for whether or not amoCl could be expected to cover an E. coli 
infection, even if the susceptibility to amoCl had not been tested itself. 
Table 2.12 shows a segment of a compiled crossABG|HAI for E. coli where the 
conditional probabilities and ORs of susceptibility are included for the antimicrobial 
listed on the left. Cases with a conditional probability of 100% gives an OR = ∞. We 
get a conditional probability of 100% when we calculate an antimicrobial’s cross-
susceptibility to itself (cefur in Table 2.12).  
HAI statistics 
 
Pathogen: E. coli 
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Antimicrobial AST statistics S R S R S R 
Ampicillin-sulbactam S 0 0 0 0 0 0 0 
J01CR01 R 0 0 0 0 0 0 0 
  Coverage ? ? ? ? ? ? ? 
  Odds ratio  ? ? ? ? ? ? 
Amoxicillin-clavulanate S 427 317 85 0 0 335 83 
J01CR02 R 251 28 201 0 0 52 188 
  Coverage 63% 92% 30% ? ? 87% 31% 
  Odds ratio  6.7 0.2 ? ? 3.8 0.3 
Piperacillin-tazobactam S 488 254 187 0 0 295 177 
J01CR05 R 74 13 52 0 0 25 46 
  Coverage 87% 95% 78% ? ? 92% 79% 
  Odds ratio  3.0 0.5 ? ? 1.8 0.6 
Cefalexin S 0 0 0 0 0 0 0 
J01DB01 R 0 0 0 0 0 0 0 
  Coverage ? ? ? ? ? ? ? 
  Odds ratio  ? ? ? ? ? ? 
Cefazolin S 20 13 0 0 0 13 0 
J01DB04 R 50 4 44 0 0 2 41 
  Coverage 29% 76% 0% ? ? 87% 0% 
  Odds ratio  8.1 0.0 ? ? 16.3 0.0 
Cefuroxime S 412 412 0 0 0 407 0 
J01DC02 R 418 0 418 0 0 13 398 
  Coverage 50% 100% 0% ? ? 97% 0% 
  Odds ratio 
 ∞ 0.0 ? ? 31.8 0.0 
Table 2.12: An example of the data on cross-susceptibility/resistance that can be obtained 
from an isolate database. 
The crossABG|HAI and crossABG|CAI compiled for Rambam each included 27 
pathogen groups and 55 * 55 pairs of antimicrobials with an entry for respectively 
cross-susceptibility and cross-resistance, respectively. This gave a total number of 
27*55*55*2 = 163,650 entries in each crossABG. As it can be seen in the data 
example in Table 2.12, some of the antimicrobials and antimicrobial combinations, 
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did not have any AST results (“0”), and thereby the probability of cross-
susceptibility/resistance could not be calculated (“?”). 
By using the Rambam AST statistics on antimicrobials tested more than 10 times, we 
could fill in 5241 (3.2%) of the entries in the crossABG|HAI and 5534 (3.4%) of the 
entries in the crossABG|CAI. 
EUCAST has designed a set of interpretative rules to assist clinical microbiologists 
in the interpretation of antimicrobial susceptibility testing. Some of the rules are 
simple, for example: “IF S. aureus is resistant to oxacillin or cefoxitin, THEN report 
as resistant to all β-lactams” and some of the rules are complicated, for example:  “IF 
Enterobacteriaceae are intermediate to tobramycin, resistant to gentamicin, and 
susceptible to amikacin, THEN report as resistant to tobramycin” (Leclercq et al., 
2013). The simple rules could be integrated directly in a crossABGs, where for 
example the probability of S. aureus being susceptibility to cefuroxime, given 
resistance to oxacillin is 0% (OR=0) and likewise for the rest of the group of β-lactam 
antimicrobials. The more complicated rules could not be transferred to the 
crossABGs. The EUCAST expert rules represent an improvement in the reporting of 
susceptibility results, but covered only 265 (0.16%) of the entries in the Rambam 
crossABGs. 
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CHAPTER 3. INTERPRETATIVE 
READING OF AST RESULTS 
This chapter describes the work done to develop and validate a mathematical method 
for interpretative reading of AST results, where probabilities of susceptibility to 
untested antimicrobials can be calculated. The resulting method generates 
ABG|ASTs, by adjusting the ABG to patient specific AST results. The content of this 
chapter is based primarily on Paper I (Andreassen et al., 2015). Figure 3.1 shows 
the relation between the content of this chapter and the rest of the thesis. 
 
 
Figure 3.1: This chapter describes the method developed to generate ABG|NOSO,AST. 
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3.1. INTRODUCTION 
From a Bayesian perspective, the instABG represents our prior evidence; the prior 
probability of susceptibility to antimicrobials. When AST results become available, 
they add more evidence to our knowledge about the susceptibility. In Paper I, we 
explored methods of interpretative reading of AST results. We used data from an 
isolate database containing 3,347 isolates with AST results, compiled between 2002 
and 2004 at Rabin Medical Center in Israel. The examples and results in this chapter 
are based on this database and the corresponding instABG and crossABG.  
 
From the crossABG (described in section 2.5), we can read the probability of 
susceptibility to an antimicrobial, given an AST result for one other antimicrobial. 
When we have multiple AST results that may affect the susceptibility to an untested 
antimicrobial, it becomes more complicated to calculate the combined effect. For an 
isolate with 21 AST results, the straightforward solution would to compile the 20-
dimensional probability matrix for cefuroxime, conditional on the other 20 AST 
results. Bayes theorem can then be used directly to calculate the posterior probability 
of susceptibility to cefuroxime. This is far from a viable solution, because it would 
be impossible to populate the 220 elements in this matrix even with an isolate database 
compiled over many years in a large hospital. 
The aim was to develop and validate a practical method for interpretative reading of 
AST results where the susceptibilities are calculated from an instABG and a 
crossABG. 
 
 
3.2. CALCULATING POSTERIOR SUSCEPTIBILITIES 
To handle the combined effect of multiple AST results, we explored several versions 
of naïve and semi-naïve Bayesian methods, to calculate the probability of 
susceptibility to antimicrobials. The naïve Bayes approach includes all significant 
ORs for cross-resistance/susceptibility and assumes mutual independence. In the 
semi-naïve Bayesian methods, only a limited number of the most significant ORs 
were used. 
Table 3.1 shows a segment of the crossABG for E. coli with OR for susceptibility to 
cefuroxime (cefur), given an AST result for another antimicrobial “A”. The relevant 
ORs are bold, for example for ampicillin (A=ampi) with AST=R, we have ORcefur|¬ampi 
= 0.63.  
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Antimicrobial A 
AST 
result 
Cefuroxime 
ORcefur|A 
p ≤ 0.1 
ORcefur|¬A 
p ≤ 0.1 
Penicillin 
Penicillin    
Ampicillin R 23 0.63 
Ampicillin-
Sulbactam 
 6.9 0.40 
Amoxicillin-
Clavulanate 
R 5.1 0.30 
Piperacillin R 4.5 0.59 
Piperacillin/ 
Tazobactam 
S 1.6 0.11 
Methicillin    
Cephalosporin 
Cephalothin R ∞ 0.60 
Cefuroxime S ∞ 0 
Ceftazidime S 3.4 0.00 
Ceftriaxone S 4.5 0 
Cefepime S 2.9 0 
Carbapenem 
Ertapenem  NS NS 
Imipenem S NS NS 
Meropenem S NS NS 
Monobactam Aztreonam S 3.4 0.01 
Glycopeptide Vancomycin    
Macrolide Erythromycin    
Tetracycline 
Minocycline S 2.2 0.55 
Tetracycline S 2.4 0.63 
Aminoglycoside 
Amikacin S 1.8 0.09 
Gentamicin S 2.0 0.14 
Tobramycin S 3.7 0.10 
Quinolone 
Ciprofloxacin S 5.0 0.18 
Ofloxacin S 5.0 0.16 
Other 
Chloramphenicol    
Clindamycin    
Colistin S NS NS 
Fusidic acid    
Rifampicin    
Sulfa-Trim S 2.0 0.52 
Table 3.1: ORs for E. coli being susceptible to cefuroxime given susceptibility test results to 
other antimicrobials. NS: Odds ratio Not Significant. Blank field: Susceptibility to this 
antimicrobial not tested. S=susceptible and R=resistant. 
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Table 3.2 shows an example of predicted susceptibilities with a naïve Bayesian 
method (Naïve) and a semi-naïve Bayesian method (min1max1). We only included 
ORs for cross resistance/susceptibility which were significantly different from 1. 
The limit of significance was arbitrarily chosen for the example in Table 3.2 as p < 
0.1. The semi-naïve Bayesian method, denoted min1max1 method only included 
the largest of the ORs for antimicrobials to which the isolate was tested susceptible 
and the smallest of the ORs amongst those tested resistant. The same principle was 
used for a min2max2 method that included the two largest and the two smallest 
ORs.  
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Antimicrobial  
class 
Antimicrobial 
AST  
result    
Probability of susceptibility (%) 
instABG Naïve min1max1 
Penicillins 
Penicillin     
Ampicillin R 31 0 0 
Ampicillin- 
sulbactam 
 53   
Amoxicillin- 
clavulanate 
R 64 99 57 
Piperacillin R 41 47 11 
Piperacillin- 
tazobactam 
S 89 100 88 
Methicillin     
Cephalosporins 
Cephalothin R 33 30 9 
Cefuroxime S 83 100 88 
Ceftazidime S 91 100 99 
Ceftriaxone S 86 100 100 
Cefepime S 90 100 100 
Carbapenems 
Ertapenem  100.0   
Imipenem S 99.8   
Meropenem S 99.3   
Monobactams Aztreonam S 86 100 98 
Glycopeptides Vancomycin     
Macrolides Erythromycin     
Tetracyclines 
Minocycline S 54 94 87 
Tetracycline S 45 83 65 
Aminoglycosides 
Amikacin S 89 100 94 
Gentamicin S 84 100 92 
Tobramycin S 81 100 89 
Quinolones 
Ciprofloxacin S 73 100 98 
Ofloxacin S 74 100 100 
Other 
Chloram-
phenicol 
    
Clindamycin     
Colistin S 98.9   
Fusidic acid     
Rifampicin     
Sulfa-Trim S 59 87 61 
Table 3.2: Calculated susceptibilities to E. coli with a naïve Bayesian method (“Naïve”) and 
a semi-naïve Bayesian method (“min1max1”) 
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3.3. VALIDATION OF THE EXPLORED METHODS 
 COMPARING NAÏVE AND SEMI-NAÏVE BAYESIAN METHODS 
Table 3.3 shows the results of using several versions of naïve and semi-naïve 
Bayesian methods. The methods are named after the number of ORs used to calculate 
posterior probabilities of susceptibility. For example, the min0max3 method includes 
zero ORs on cross-resistance and the three highest significant ORs on cross-
susceptibility (if they exist). The methods were validated by using a 5-fold cross 
validation, where each time one of the five sets was designated as the validation set, 
with the remaining four forming the learning set. The instABGs and crossABGs 
compiled from the learning set were used to calculate posterior probabilities in the 
validation set. We removed the AST results one at a time and used the different 
methods to calculate the given susceptibility. Then the normalised Brier 
distance(Brier, 1950) between the AST result and the calculated susceptibility was 
used to measure the quality of the calculated susceptibility. Table 3.3 shows the 
square root of the mean Brier distance of the estimated susceptibilities for the five 
validations sets, and the range the sets varied across. 
Number 
of ORs 
Method 
Norm. Brier 
Distance (%) 
Range for  
the 5 validation sets 
0 instABG 37.7 37.3 - 38.4 
1 
min0max1 35.3 34.8 - 35.6 
min1max0 36.7 36.1 - 37.5 
2 
min0max2 37.2 37.1 - 37.4 
min1max1 25.6 25.3 - 26.0 
min2max0 40.2 39.5 - 40.8 
3 
min0max3 38.2 38.0 - 38.4 
min1max2 26.0 25.7 - 26.1 
min2max1 26.7 26.2 - 27.2 
min3max0 42.1 41.3 - 42.9 
4 
min0max4 38.6 38.4 - 38.9 
min1max3 27.0 26.6 - 27.3 
min2max2 25.3 24.8 - 25.6 
min3max1 28.5 28.1 - 28.9 
min4max0 43.0 42.3 - 43.9 
6 min3max3 26.0 25.7 - 26.4 
8 min4max4 26.7 26.4 - 27.1 
All naïve 28.2 27.8 - 28.5 
Table 3.3: Normalised Brier distances for calculated susceptibilities by using different 
Bayesian approaches. 
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The normalised Brier distance between the instABG probabilities and the AST results 
for all isolates in the database was 37.7%. By generating patient specific ABG|ASTs 
with the naïve Bayes method we reduced the distance to 28.2%. We achieved the 
smallest distance of 25.3% with ABG|ASTs calculated by using the semi-naïve 
min2max2 method.  
The Brier distances from the 5-fold validation were significantly smaller (p<10-99, 
paired 2-tailed t-test) for the min2max2 method than for the instABG. The distance 
for the min2max2 was also significantly smaller than the distance for the min1max1 
method (p<10-9). The naïve Bayes approach is known to produce overconfident 
results, i.e. results too close to 0% or 100%, if the underlying assumption of 
independence is not well met. The naïve Bayes results in Table 3.3 indicates that this 
is the case, and this is most likely the reason that the semi-naïve methods perform 
better than the naïve method.  
 
 PERFORMANCE ON DIFFERENT PATHOGEN GROUPS 
Figure 3.2 shows the performance of the min2max2 method on each pathogen group 
compared to the prior susceptibilities from the instABG. The presented normalised 
Brier distances for each pathogen group were averaged over the five validation sets. 
The normalised Brier distance was reduced with 13.3% for GN bacteria, 12.0% for 
Staphylococcus spp. and 3.5% for the rest of the GP bacteria on average. This 
indicates a better performance on GN isolates compared to GP isolates. This is could 
be related to a higher fraction of the cross-ABG being filled for GN bacteria, i.e. a 
higher fraction of significant cross-resistances and cross-susceptibilities.  
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Figure 3.2: Normalised Brier distances for each pathogen group averaged over 5 validation 
sets when using prior susceptibilities and the min2max2 method, respectively. 
 
 PERFORMANCE WITH DIFFERENT P-VALUES 
The results were generated with ORs for-cross resistance/susceptibility with the limit 
of significance p < 0.1. We explored how the limit of significance influenced the 
results. The results for different p values, ranging from 0.02 to 0.5 are illustrated on 
Figure 3.3, for respectively the prior susceptibilities from the instABG, the naïve 
Bayes method, and the min2max2 method. 
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Figure 3.3: Normalised Brier distances averaged over the five validation sets when using 
respectively the prior susceptibilities from the instABG, the naïve Bayes method, and the 
min2max2 method to calculate patient specific probabilities of susceptibility. The results 
were generated with different p values, ranging from 0.02 to 0.5. 
 
It can be seen from Figure 3.3 that irrespective of p value, the naïve Bayes method 
had lower normalised Brier distance than the prior probabilities and that the 
min2max2 method had lower normalised Brier distances than the naïve Bayes 
method. The decrease of the normalised Brier distance of the min2max2 method with 
the p value could be seen as an argument for using a high p value. This should 
however be balanced against the risk of obtaining “strange” estimates due to spurious 
ORs derived from very few susceptibility results. Since the reduction in normalised 
Brier distance was very small for p values above 0.1, p = 0.1 may be an appropriate 
choice. 
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3.4. DISCUSSION AND CONCLUSION 
In conclusion, we achieved significantly more accurate predictions of microbial in 
vitro susceptibility to antimicrobials, than the prior probabilities stored in the 
instABG. The developed method is limited by being an approximate method. 
However, an exact Bayesian approach would require multidimensional conditional 
probability matrices, which is far beyond reach. The one-dimensional conditional 
probabilities in the crossABG represents a practical upper limit. It may therefore be 
considered a virtue, that useful posterior probabilities can be calculated from the 
limited information compiled from the isolate database. 
The method was implemented in TREAT Steward. When possible the system used 
the min2max2 method, except when less than two ORs were available for cross-
susceptibility and cross-resistance, respectively, in which case min1max1 was used. 
The implementation will be presented in Chapter 7. 
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CHAPTER 4. THE EFFECT OF PRIOR 
ANTIMICROBIAL EXPOSURE 
This chapter describes the work done to quantify the effect of prior antimicrobial 
exposure at patient level. A quantification of increased resistance associated with 
prior antimicrobial exposure is a necessary step to be able to generate an ABG|PE 
for patients previously exposed to antimicrobials. The content of the chapter is based 
primarily on Paper II (Sanden et al., 2016). Figure 4.1 shows the relation between 
the content of this chapter and the rest of the thesis. 
 
 
Figure 4.1: This chapter describes the work done to quantify the effect of PE with the 
purpose of being able to generate an ABG|NOSO,PE. 
 
4.1. INTRODUCTION AND METHOD 
The aim of the research published in Paper II was to quantify the association between 
recent antimicrobial exposure at patient level and subsequent antimicrobial 
resistance. Data were obtained from a series of prospective cohort studies carried out 
at Rabin Medical Center, Beilinson Hospital in Israel in the period from 2002-2011, 
where 4,232 patients suspected of infection were included. We analysed resistance to 
antimicrobials in bacterial isolates from patients with clinically significant and 
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microbiologically documented infections, starting antimicrobial treatment after 
obtaining cultures (n=775). Further details on the inclusion criteria are available in 
Paper II  (Sanden et al., 2016). 
Separate analyses were made for Gram negative (GN) and Gram positive (GP) 
bacterial isolates. The increase in bacterial resistance is expressed by ORs and 95% 
Confidence Intervals (CI) (Sanden et al., 2016). We calculated increased resistance 
to both single antimicrobials and to the following classes of antimicrobials: 
 Tetracyclines 
 Penicillins 
 Penicillins combined with β-lactamase inhibitor (BLI) 
 Cephalosporins 
 Aminoglycosides 
 Carbapenems 
 Quinolones 
The increase in resistance was calculated after the following types of exposure were 
analysed:  
 Exposure to any antimicrobial class 
 Exposure to the same antimicrobial class 
 Exposure to other antimicrobial classes 
 
 
4.2. RESISTANCE IN GN BACTERIA TO SINGLE 
ANTIMICROBIALS 
Figure 4.2 illustrates the ORs for increased resistance in GN bacterial isolates from 
patients exposed to any antimicrobial compared to those with no exposure. The effect 
of exposure to any class ranged from an insignificant OR of 1.03 for chloramphenicol 
to a significant OR of 9.84 for imipenem-cilastatin.  
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Figure 4.2: OR for increased resistance in Gram negative bacteria from patients exposed to 
any antimicrobial compared to unexposed. Each antimicrobial is presented with number of 
AST results [in brackets]. Vertical bars indicate 95% confidence limits. 
 
Looking at resistance to antimicrobials within the same class, the prior exposure had 
almost the same effect on all antimicrobials within the same class. The only 
significant exception was amongst the carbapenems, where previous exposure to any 
class of antimicrobials had a greater effect on resistance to imipenem-cilastatin 
(OR=9.8) than to ertapenem (OR=2.6) or meropenem (OR=1.5). 
GN bacteria from patients exposed to the same antimicrobial class as the tested 
antimicrobial, only showed significant ORs for quinolones, with an OR of 7.15 for 
ofloxacin and an OR of 5.11 for ciprofloxacin. The data for this analysis were sparse, 
since patients were seldom treated with the same antimicrobial twice within a month. 
Looking at exposure to an antimicrobial from another class, the majority of the 
antimicrobials with significantly higher resistance when exposed to any class also 
had significant ORs after exposure to another class of antimicrobials. This indicates 
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an effect of cross-resistance between antimicrobial classes. The highest OR for 
increased resistance after exposure to an antimicrobial from another class was for 
nitrofurantoin with OR 5.92 (2.02-17.38). Table 4.1 shows the analysis for the three 
most common prior antimicrobial treatments of patients with current infection with 
GN bacteria. Data details for all the 26 included antimicrobials are available in Paper 
II (Appendix II) (Sanden et al., 2016). For example, for ceftriaxone (cftax) the 
probability of resistance goes from being 27% for no exposure to 44% for patient 
previously exposed to any antimicrobial within the last month, resulting in a OR of 
2.1(1.2-3.5). After exposure to a cephalosporin (same class), resistance to cftax 
increased with an OR of 2.3 (0.8–7.0) and after exposure to another class, resistance 
to cftax increased with an OR of 3.1 (1.8–5.3). In general resistance was increased 
most by exposure to the same class following by exposure to any class and other 
class. 
 
Tested  
antimicrobial 
Type of prior antimicrobial exposure 
None Any class Same class Other class 
Res Res OR (95% CI) Res OR (95% CI) Res OR (95% CI) 
Ampicillin- 
clavulanate 
41 % 60 % 2.1 (1.2-3.7) 73 % 3.8 (1.0–4.4) 57 % 1.8 (1.0–3.4) 
Ceftriaxone 27 % 44 % 2.1 (1.2–3.5) 46 % 2.3 (0.8–7.0) 42 % 1.9 (1.1–3.4) 
Ciprofloxacin 30 % 61 % 3.6 (2.2–5.7) 69 % 5.1 (1.7–15.0) 57 % 3.1 (1.8–5.3) 
Table 4.1: Resistance to the three most common prior antimicrobial treatments of patients 
with infected with GN bacteria. (Res = Probability of resistance) 
 
4.3. RESISTANCE IN GP BACTERIA TO SINGLE 
ANTIMICROBIALS 
The results of the analysis of resistance in GP are illustrated on Figure 4.3. The 
number of AST results was considerably lower for GP bacteria than for GN bacteria, 
and the results did not show any significant increase in resistance after exposure to 
antimicrobials. 
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Figure 4.3: OR for increased resistance in GP bacteria from patients exposed to any 
antimicrobial compared to unexposed. Each antimicrobial is presented with number of AST 
results [in brackets]. Vertical bars indicate 95% confidence limits. 
 
4.4. RESISTANCE IN GN BACTERIA TO CLASSES OF 
ANTIMICROBIALS 
For seven classes of antimicrobials, Figure 4.4 illustrates the ORs for increased 
resistance in bacterial isolates from patients exposed to any antimicrobial compared 
to those with no exposure. Across the antimicrobial classes, the results indicated a 
ranking of antimicrobials with quinolones and carbapenems being most effected by 
prior antimicrobial exposure, followed by aminoglycosides, penicillins+BLI, and 
cephalosporins. 
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Figure 4.4: OR for increased resistance in GN bacteria to antimicrobial classes, when 
analysing isolates from patients exposed to any antimicrobial. Each antimicrobial class is 
presented with number of AST results [in brackets]. Vertical bars indicate 95% confidence 
limits. 
 
4.5. DISCUSSION AND CONCLUSION 
In conclusion, we were able to quantify the association between antimicrobial 
exposure and subsequent resistance at the level of the individual treated. Our results 
showed that an increase in resistance after exposure to antimicrobials was driven by 
both exposure to the same class, as well as by cross-resistance after exposure to other 
antimicrobial classes. However, to be fully applicable in clinical use, the analysis 
should be expanded to give pathogen- and antimicrobial-specific results. These 
expansions would require a substantially larger dataset.  
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Figure 4.5: The selection of data on prior exposure for a specific pathogen (E. coli) and a 
specific antimicrobial (cftax). 
Our study included 4,232 patients with 775 clinically significant isolates, (Figure 
4.5). As illustrated on Figure 4.5, 85 of these isolates were from patients with PE to 
a single antimicrobial. When analysing a specific pathogen, for example E. coli, we 
were left with 23 isolates and the most common PE, cftax, were only associated with 
3 of these isolates. Even through the study included more than 4000 patients, this was 
far from being enough data to generate pathogen- and antimicrobial specific results 
with convincing statistical power, and it would be logistically difficult to collect 
enough data. 
Our results on exposure to any, same and other antimicrobials do however indicate a 
need to modify the expected coverage of empirical antimicrobial treatments for 
patients recently exposed to antimicrobials. This was a motivation for exploring 
another approach to modify the ABG|HAI or ABG|CAI for patients previously 
exposed to antimicrobials, which will be addressed in Chapter 5. 
4232 Patients
775 Isolates = MDI
85 PE = monotherapy
23 Pathogen = E. coli
3 PE=cftax
CHAPTER 5. MODIFYING THE ABG TO ACCOUNT FOR PE 
 
58 
CHAPTER 5. MODIFYING THE ABG TO 
ACCOUNT FOR PE 
This chapter describes a mathematical method (patent pending) developed to modify 
either the ABG|CAI or the ABG|HAI with respect to a patient’s prior antimicrobial 
exposure. This chapter serves as an operationalisation of Paper II (described in 
Chapter 4). The method will be described by giving a patient example, and the 
generalised mathematics is described in Appendix A. Figure 5.1 shows the relation 
between the content of this chapter and the rest of the thesis. 
 
Figure 5.1: This chapter describes the method used to generate ABG|NOSO,PE. 
 
5.1. THE SUSCEPTIBILITY TO AN ANTIMICROBIAL AFTER PE 
TO THE SAME ANTIMICROBIAL CLASS 
To modify the susceptibility to an antimicrobial, given PE to that antimicrobial, we 
need the corresponding OR for increased resistance. In the study (Sanden et al., 
2016), described in Chapter 4, we observed that PE had almost the same effect on all 
antimicrobials within the same class. From Paper II (Sanden et al., 2016) we have 
ORs for increased resistance to  antimicrobial classes in GN bacteria (Table 5.1). The 
ORs are associated with PE to any, same, and other class of antimicrobial, 
respectively.  
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GN bacteria 
 
PE=any class 
 
PE=same class 
 
PE=other class 
Tested  
antimicrobial class 
N ORclass (95% CI) N ORclass (95% CI) N ORclass (95% CI) 
Tetracyclines 514 1.52 (0.66-3.49)  <10   512 1.45 (0.63-3.35) 
Penicillins 1028 1.76 (0.96-3.25)  <10   1012 1.75 (0.95-3.23) 
Cephalosporins 2425 2.16 (1.16-4.01) 2110 1.52 (0.37-6.29) 2339 2.10 (1.05-4.21) 
Penicillins + BLI 1100 2.42 (1.23-4.79) 960 2.55 (0.59-11.03) 1064 2.36 (1.04-5.33) 
Aminoglycosides 1278 2.84 (1.55-5.22)  <10   1262 2.46 (1.30-4.64) 
Carbapenems 863 3.13 (0.44-22.25)  <10   848 1.77 (0.21-14.88) 
Quinolones 1060 3.35 (2.05-5.47) 917 6.02 (1.90-19.12) 1004 2.67 (1.43-4.98) 
Table 5.1: ORs for increased resistance in GN bacteria associated with exposure to 
respectively any, same, and other class of antimicrobial (Sanden et al., 2016). 
 
It was difficult to generate significant ORs for increased resistance, given exposure 
to the same class. This was probably due to the limited number of patients with PE 
and corresponding AST result on the same class of antimicrobials. However, for a 
given antimicrobial “A”, OR¬a|PE=same could be expected to higher or at least equal to 
OR¬a|PE=any. Where OR¬a|PE=same describes the change in resistance towards 
antimicrobial A, given PE to an antimicrobial of the same class, and OR¬a |PE=same, 
describes the change in resistance towards A, given exposure to any type of 
antimicrobial. In the following we will use OR¬a|PE=any to modify the susceptibility to 
previously given antimicrobials. This means that we, for example, assume 
conservatively for cephalosporins that OR¬ceph|PE=same = 2.16. 
Consider as an example, a patient suspected of being infected with a community-
acquired E. coli infection. For this patient, the ABG|CAI (described in Chapter 2, 
section 2.3) can be used for guidance on empirical treatment. A small segment of the 
55 antimicrobials in the Rambam ABG|CAI for E. coli is shown Table 5.2. 
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ABG|CAI 80% 94% 50% 71% 75%        
PE     X    OR¬ceph|PE=ceph 
ABG|CAI,PE P*(amoCl) P*(pipTa) P*(cefa) P*(cefur) P*(cftax)     
Table 5.2: A segment of the ABG|CAI from Rambam, listing the susceptibility of E. coli. The 
patient specific susceptibility after PE to ceftriaxone will be shown in the ABG|CAI,PE. 
If the medical history for this patient includes recent antimicrobial treatment, then the 
probability of resistance to antimicrobials could be expected to increase (Bell et al., 
2014; Costelloe et al., 2010; Sanden et al., 2016), as demonstrated in Chapter 4. The 
susceptibilities in the ABG|CAI, should then be modified with respect to the effect 
of the patients PE. The resulting probabilities is the represented in an ABG|CAI,PE. 
Consider as an example, a patient with PE=cftax. The prior probability of 
susceptibility to cftax, can be read from the ABG|CAI to be P(cftax)=75% (Table 
5.2). By modifying P(cftax) with the OR for increased resistance to a cephalosporin 
given PE to a cephalosporin, denoted OR¬ceph|PE=ceph, we get P*(cftax).  
In the following we will calculate P*(cftax). The probability of resistance to cftax, is 
denoted P(¬cftax), where P(cftax)=1-P(¬cftax). First, the prior odds ODcftax for 
susceptibility to cftax is calculated from the prior probability of susceptibility, 
P(cftax), as: 
𝑂𝐷cftax =
𝑃(cftax)
𝑃(¬cftax)
=  
0.75
1−0.75
= 3  
The prior odds are then modified with OR¬ceph|PE=ceph=2.16. The posterior odds for 
susceptibility to cftax after exposure to cftax, is denoted OD*cftax. By using Eq. 4 and 
Eq. 10 from Appendix A, OD*cftax can be calculated as: 
𝑂𝐷𝑐𝑓𝑡𝑎𝑥
∗ = 𝑂𝐷cftax ∙  
1
𝑂𝑅¬𝑐𝑒𝑝ℎ|𝑃𝐸=𝑐𝑒𝑝ℎ
= 3 ∙  
1
2.16
= 1.40    
The posterior probability of susceptibility, denoted P*(cftax), can then be calculated 
by using the mathematical relationship between odds and probability: 
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𝑂𝐷∗cftax =
𝑃∗(𝑐𝑓𝑡𝑎𝑥)
𝑃∗(¬𝑐𝑓𝑡𝑎𝑥)
  
 ⇔ 
𝑃∗(cftax) =  
𝑂𝐷∗cftax
1+ 𝑂𝐷∗cftax
=
1.4
1+1.4
= 0.58 = 58%    
This means that for the patient previously has been treated with cftax, then the 
probability of cftax being effective against an E. coli goes from being 75% to 58%, 
which makes the antimicrobial less attractive to use. We can now fill in the 
susceptibility to cftax in an ABG|CAI,PE, as shown in Table 5.3. 
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ABG|CAI 80% 94% 50% 71% 75%        
PE     X    OR¬ceph|PE=ceph 
ABG|CAI, PE P*(amoCl) P*(pipTa) 34% 53% 58%     
Table 5.3: A segment of the ABG|CAI from Rambam, listing the susceptibility of E. coli. The 
ABG|CAI,PE, now includes the susceptibility of E. coli to ceftriaxone (PE) and the 
susceptibility to antimicrobials of the same class (cephalosporins) 
The susceptibilities to the other cephalosporins are likewise calculated by modifying 
the prior susceptibility from the ABG|CAI with OR¬ceph|PE=ceph. 
 
5.2. THE SUSCEPTIBILITY TO AN ANTIMICROBIAL AFTER PE 
TO OTHER CLASSES OF ANTIMICROBIALS 
The question is now, how to modify the susceptibilities to the antimicrobials from 
other classes in the ABG|CAI, PE. Our study, described in Chapter 4 (Sanden et al., 
2016), showed increased resistance after exposure to antimicrobials from another 
class, and hence we would in our example also expect PE to cftax to affect the 
susceptibility to other antimicrobials. For the given example, we need for the OR for 
increased resistance to amoCl and to pipTa, given exposure to cftax. Unfortunately, 
no studies have to our knowledge been able to assess the increased resistance of a 
given pathogen after exposure to different antimicrobials. This was a motivation for 
CHAPTER 5. MODIFYING THE ABG TO ACCOUNT FOR PE 
 
62 
inventing a method that takes advantage of our knowledge on cross-resistance 
between antimicrobials.  
The cross-resistance between cftax and the other antimicrobials from our example (in 
Table 5.3) are shown in the crossABG|CAI in Table 5.4. Here we can read that the 
probability of susceptibility to amoCl given resistance to cftax, 
P(amoCl|¬cftax)=39%. The change in susceptibility from P(amoCl)=80% to 
P(amoCl|¬cftax)=39% corresponds to an ORamoCl|¬cftax=0.16. 
 
 
Table 5.4: The crossABG|CAI with cross-susceptibility/resistance between 
ceftriaxone/amoxicillin-clavulanate and ceftriaxone/piperacillin-tazobactam. 
 
As a consequence of the cross-resistance between cftax and amoCl, we modify the 
susceptibility to amoCl, given PE to cftax.  
By using Eq. 8 from Appendix A, the probability of susceptibility to amoCl given PE 
to cftax can be calculated as: 
𝑃∗(𝑎𝑚𝑜𝐶𝑙) = 𝑃(𝑎𝑚𝑜𝐶𝑙|𝑐𝑓𝑡𝑎𝑥) ∙ 𝑃∗(𝑐𝑓𝑡𝑎𝑥) + 𝑃(𝑎𝑚𝑜𝐶𝑙|¬𝑐𝑓𝑡𝑎𝑥) ∙ 𝑃∗(¬𝑐𝑓𝑡𝑎𝑥) 
From the crossABG|CAI (Table 5.4) we can read that: 
 P(amoCl|cftax) = 0.91 
 P(amoCl|¬cftax) = 0.39 
From Table 5.3 we have  
P*(cftax) = 58%, and P*(¬cftax) = 1- P*(cftax) =42%. By inserting these values, we 
get: 
𝑃∗(𝑎𝑚𝑜𝐶𝑙) = 𝑃(𝑎𝑚𝑜𝐶𝑙|𝑐𝑓𝑡𝑎𝑥) ∙ 𝑃∗(𝑐𝑓𝑡𝑎𝑥) + 𝑃(𝑎𝑚𝑜𝐶𝑙|¬𝑐𝑓𝑡𝑎𝑥) ∙ 𝑃∗(¬𝑐𝑓𝑡𝑎𝑥) 
=  0.91 ∙  0.58 +  0.39 ∙  0.42 = 0.69 = 69% 
crossABG|CAI 
Pathogen: E. coli 
Ceftriaxone  
cftax ¬cftax 
Amoxicillin-clavulanate P(amoCl|CFTAX) 91% 39% 
J01CR02 ORamoCl|cftax 2.57 0.16 
Piperacillin-tazobactam P(pipTa|CFTAX) 96% 86% 
J01CR05 ORpipTa|cftax 1.53 0.42 
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This means that for a patient previously treated with cftax, the probability of amoCl 
being effective against an E. coli infection goes from being 80% to 69%. We can now 
fill in the susceptibility to amoCl in the ABG|CAI, PE as shown in Table 5.5. The 
result of the similar calculation made for pipTa can also be seen in Table 5.5. 
 
Table 5.5: A segment of the ABG|CAI from Rambam, listing the susceptibility of E. coli. The 
ABG|CAI,PE, now includes the susceptibility of E. coli to ceftriaxone (PE) and the 
susceptibility to antimicrobials of the same class (cephalosporins) and the susceptibility to 
antimicrobials of another class (penicillins). 
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ABG|CAI 80% 94% 50% 71% 75%        
PE     X    OR¬ceph|PE=ceph 
ABG|CAI,PE 69% 92% 34% 53% 58%     
  P(pipTa|CFTAX)     
  P(amoCl|CFTAX) 
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CHAPTER 6. MODIFYING THE ABG TO 
ACCOUNT FOR BOTH PE AND AST 
This chapter describes a mathematical method (patent pending) developed to modify 
either the ABG|CAI or the ABG|HAI with respect to both patient specific PE and AST 
results. Figure 6.1 shows the relation between the content of this chapter and the rest 
of the thesis. 
 
Figure 6.1: This chapter describes the method used to generate ABG|NOSO,PE,AST. 
 
When AST results become available for patients previously exposed to 
antimicrobials these results should also be used to modify the susceptibility to 
untested antimicrobials (as described in Chapter 3). Now we need an patient specific 
ABG that accounts for both PE and AST results, denoted as ABG|CAI,PE,AST. 
Consider the situation, where an AST result is available, showing that E. coli is 
susceptible to cefuroxime (cefur). An ABG|CAI,PE,AST is added in Table 6.1, where 
the confirmed susceptibility to cefur is expressed as 100% probability of 
susceptibility. 
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ABG|CAI 80% 94% 50% 71% 75% 
PE     X 
ABG|CAI,PE 69% 92% 34% 53% 58% 
AST    S  
ABG|CAI,PE,AST ? ? ? 100% ? 
Table 6.1: A segment of the Rambam ABG|CAI, listing susceptibilities for E. coli. The 
ABG|CAI,PE accounts for PE to ceftriaxone and the ABG|CAI,PE,AST, will account for both 
PE to ceftriaxone and for the AST result: cefuroxime=S.   
 
To express the effect of both PE=cftax and AST for cefur=S, we will use an OR for 
each factor affecting the susceptibility. Taking amoCl as example, the OR for 
susceptibility to amoCl, after exposure to cftax, is denoted ORamoCl|PE=cftax, and is 
calculated as: 
𝑂𝑅𝑎𝑚𝑜𝐶𝑙|𝑃𝐸=𝑐𝑓𝑡𝑎𝑥 =
𝑂𝐷𝑎𝑚𝑜𝐶𝑙
∗
𝑂𝐷𝑎𝑚𝑜𝐶𝑙
 =
𝑃∗(𝑎𝑚𝑜𝐶𝑙)
𝑃∗(¬𝑎𝑚𝑜𝐶𝑙)
∙
𝑃(¬𝑎𝑚𝑜𝐶𝑙)
𝑃(𝑎𝑚𝑜𝐶𝑙)
=  
0.69
0.31
∙
0.20
0.80
= 0.56 
Where P(amoCl)=80% comes from the Rambam ABG|CAI and P*(amoCl)=69% 
comes from the ABG|CAI, PE (Table 6.1). From the crossABG|CAI we have the OR 
for susceptibility to amoCl given cefur=S, ORamoCl|cefur=4.73 (Table 6.2).  
 
CAI statistics 
 
Pathogen: E. coli 
   C
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Antimicrobial AST statistics S R 
Amoxicillin-clavulanate S 4914 4058 532 
J01CR02 R 1226 214 827 
  Coverage 80.0% 95.0% 39.1% 
  Odds ratio  4.73 0.16 
Table 6.2: The crossABG|CAI for susceptibility/resistance between cefuroxime and 
amoxicillin-clavulanate. 
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The next step was to combine the effect of PE and AST results. In Chapter 3 we took 
advantage of the semi-naïve Bayesian methods min1max1 and min2max2, to 
calculate the probability of susceptibility. These methods were also used to modify 
the ABG to multiple PE’s and AST results. The methods use the largest available 
ORs for increased resistance and the smallest ORs for decreased resistance. In the 
given example, we use min1max1 to write:  
𝑂𝑅𝑎𝑚𝑜𝐶𝑙
∗   = 𝑂𝑅𝑎𝑚𝑜𝐶𝑙|𝑃𝐸=𝑐𝑓𝑡𝑎𝑥 ∙ 𝑂𝑅𝑎𝑚𝑜𝐶𝑙|𝑐𝑒𝑓𝑢𝑟  = 0.56 ∙ 4.73 = 2.63 
By using Eq. 4 from Appendix A, we can calculate the odds of susceptibility to 
amoCl: 
𝑂𝐷𝑎𝑚𝑜𝐶𝑙
∗ = 𝑂𝑅𝑎𝑚𝑜𝐶𝑙
∗   ∙ 𝑂𝐷𝑎𝑚𝑜𝐶𝑙  = 2.63 ∙  
0.80
0.20
 = 10.52 
Finally, the posterior probability of susceptibility to amoCl is calculated as: 
𝑃∗(𝑎𝑚𝑜𝐶𝑙) =
𝑂𝐷′𝑎𝑚𝑜𝐶𝑙
1+𝑂𝐷′𝑎𝑚𝑜𝐶𝑙
=  
10.52
1+10.52
= 0.91 = 91% 
Thereby the probability of in vitro susceptibility to amoCl, given PE=cftax and 
cefur=S is 91%. The results of the similar calculations made for the other 
antimicrobials can be seen in Table 6.3. 
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ABG|CAI 80% 94% 50% 71% 75% 
PE     X 
ABG|CAI, PE 69% 92% 34% 53% 58% 
AST    S  
ABG|CAI, PE, AST 91% 97% 73% 100% 100% 
Table 6.3: A segment of the Rambam ABG|CAI, listing susceptibilities for E. coli. The 
ABG|CAI,PE accounts for PE to ceftriaxone and the ABG|CAI,PE,AST, now accounts for 
both PE to ceftriaxone and for the AST result: cefuroxime=S.   
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Table 6.4 shows an ABG|CAI,PE,AST were an E. coli isolate was tested resistant to 
cefur. It can be seen that the AST result for cefur affects the susceptibility both to the 
other cephalosporins and also to the penicillins. Due to cross-resistance between 
cefur and cefazolin the AST result cefur=R, results in 0% susceptibility to cefazolin. 
Cross-resistance between cefur and the penicillin amoCl gives a decrease in the 
susceptibility to amoCl from 69% to 27%.  It can also be seen from Table 6.3 and 
Table 6.4 that the AST result for cefur, had a stronger effect on the other 
cephaloporins, than on the penicillins. 
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ABG|CAI 80% 94% 50% 71% 75% 
PE     X 
ABG|CAI, PE 69% 92% 34% 53% 58% 
AST    R  
ABG|CAI, PE, AST 27% 81% 0% 0% 3% 
Table 6.4: A segment of the Rambam ABG|CAI, listing susceptibilities for E. coli.  The 
ABG|CAI,PE accounts for PE to ceftriaxone and the ABG|CAI,PE,AST, now accounts for 
both PE to ceftriaxone and for the AST result: cefuroxime=R.   
 
This example included the susceptibility to five antimicrobials, but the principles for 
modifying the in vitro susceptibilities would be the same for the rest of the 
antimicrobials available at a given location.  
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CHAPTER 7. IMPLEMENTING THE 
PERSONALISED ABG 
The developed in vitro susceptibility modifications were implemented in a software 
solution for antimicrobial stewardship (TREAT Steward). This chapter illustrates the 
implementation by going through a patient example. 
During the project, we focused on making the research operational, by developing 
practical applications, with the aim of shortening the way from research to an 
implemented solution available for clinicians and patients. Handling the patient 
specific factors that can affect the institutional ABG, can be a complicated task for 
the clinician, who must choose the most appropriate antimicrobial. A software-based 
application incorporating the expected effect of the patient specific factors could 
serve as decision support for clinicians, in the process of selecting the antimicrobial 
treatment.  
 
7.1. TREAT STEWARD 
The developed methods were implemented in a software solution for antimicrobial 
stewardship, TREAT Steward (TREAT), which has been shown to reduce 
inappropriate antimicrobial treatments at hospitals (Paul et al., 2006).  TREAT uses 
Causal Probabilistic Network (CPN) technology. CPNs, also called Bayesian 
networks, can for example, represent the probabilistic relationships between diseases 
and symptoms. TREAT provides decision support by calculating the probability of 
infection, the most likely diagnosis and the responsible pathogen(s). From this, a cost-
benefit analysis balances the benefits (survival) and costs (side-effects, resistance 
development, direct costs) of potential antimicrobial treatment regimens 
(TREATsystems.com, 2017).  
Figure 7.1 and Figure 7.2 show the graphical user interface for the decision support 
feature in TREAT. Figure 7.1 shows a summary of the findings for a fictive patient 
example, a 71-year-old male with symptoms indicating pneumonia. 
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Figure 7.1: The user interface of TREAT showing a summary of the findings for a fictive 
patient. 
Figure 7.2 shows the user interface of the decision support feature in TREAT, for the 
patient example in Figure 7.1. On the left side, the “TREAT diagnosis” suggests 
100% probability of pneumonia. In the middle, the suggested pathogen distribution 
is shown and on the right side of Figure 7.2, the recommended antimicrobial 
treatments are shown; the top 1 treatment recommendation in this case being 
ampicillin. For each of the pathogens the probability of coverage by ampicillin is 
indicated by the blue portion of the bar, with red indicating not covered. 
Figure 7.2: The user interface of TREAT showing the decision support feature. 
The in vivo coverage of ampicillin across all pathogens in the suggested pathogen 
distribution is 61% (shown in heading above the pathogen distribution).  
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7.2. IMPLEMETATION IN TREAT STEWARD  
The work presented in this thesis contributed to the TREAT system by providing 
methods to estimate personalised in vitro susceptibilities. The methods for in vitro 
susceptibility modifications were integrated with the in vivo susceptibility 
modifications already made by TREAT (Figure 7.3).  
 
Figure 7.3: By implementing the developed methods for in vitro susceptibility modifications 
in TREAT susceptibilities in vivo susceptibility modifications already made by TREAT. 
The in vivo modifications in TREAT are specified by the user for each infection site. 
This includes adjustments to the bioavailability and penetrance (e.g. of the blood-
brain barrier) as well as adjustments for the effect of bacteriostatic versus bactericidal 
treatments. 
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7.3. PATIENT EXAMPLE 
In the following the implementation of the personalised ABGs into the TREAT 
system will be illustrated by going through a patient example. Consider the patient 
example from section 7.1, where no PE or AST results are affecting the susceptibility. 
The probabilities of susceptibility are in this case solely based on the ABG|CAI. 
Table 7.1 shows a segment of the implemented ABG|CAI and Table 7.2 explains the 
color-codes used in the implemented ABGs.   
 
Table 7.1: A segment of an implemented ABG|CAI showing probability of in vitro 
susceptibility for different pathogen/antimicrobial combinations.  
 
0.0-4.9 5.0-14.9 15.0-24.9 25.0-34.9 35.0-44.9 45.0-54.9 55.0-64.9 65.0-74.9 75.0-84.9 85.0-94.9 95.0-100 
Table 7.2: The color-scale used to indicate the probability of susceptibility. Red indicates a 
low  coverage, yellow indicates intermediate coverage, and green indicates high coverage. 
Figure 7.4 shows the advice given by TREAT, when no PE or AST results are entered 
for the patient. TREAT now provides the opportunity to enter PE (“Antibiotics last 
month”). In this example ceftriaxone is entered (Figure 7.5). The recalculated advice, 
which takes PE into account, can be seen on Figure 7.6.  
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Figure 7.4: The TREAT advice when no PE and no AST. 
Figure 7.5: Ceftriaxone is entered in as PE 
Figure 7.6: The TREAT advice when PE=ceftriaxone and no AST. 
Figure 7.7: The AST result is entered: strep. pneumoniae is tested resistant (R) to 
amoCl.  
 
Figure 7.8: The TREAT advice when PE=ceftriaxone and AST for strep. pneumonia: 
amoCl=R. 
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When ceftriaxone is entered as PE (Fig. 7.5), the recalculated susceptibilities results 
in a new order of the recommended treatments. The in vivo coverage of ampicillin is 
affect by PE to ceftriaxone and consequently decreases from 61% (Fig. 7.4) to 58% 
(Fig. 7.6). The susceptibility to azithromycin is not affected, and hence azithromycin 
is now the top 1 recommendation instead of ampicillin. The decreased coverage of 
ceftriaxone itself results it in going from being the top 5 recommendation to drop 
down to be recommendation number 9 (see the red arrow). 
When the AST result is entered that amoCl=R (Fig. 7.7), ampi is consequently not 
one of the recommended treatments (Fig. 7.8). Cross-resistance between amoCl and 
ampi results in a decreased probability of susceptibility to ampi, when resistance is 
observed towards amoCl. 
As a part of the project, a feature to inspect the ABG was also implemented. Figure 
7.9 shows an example of the implemented feature, in this case showing the 
susceptibility of strep. pneumonia to ceftriaxone. The susceptibility modification is 
illustrated on a bar representing susceptibility from 0 to 100%. The susceptibility 
from the ABG|CAI is indicated by a “●”. Modifications made due to PE and/or AST 
results are indicated by a “◄”. The green bar indicates the final susceptibility after 
in vivo modifications are made. In this example the susceptibility was not decreased 
by in vivo modifications.   
 
Figure 7.9: An example of the implemented feature to inspect the probability of 
susceptibility. The example presents an ABG|CAI,PE,AST for the susceptibility of strep. 
pneumonia to ceftriaxone, when PE=ceftriaxone and AST: amoCl=R. 
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Figure 7.10 shows additional versions of the ABG for the same patient. It can be seen 
that when PE=cftax is entered, then the susceptibility to cftax and ampi is decreased 
(ABG|CAI vs. ABG|CAI,PE). When an AST result is entered: amoCl=R, then the 
susceptibility to ampi and cftax is further decreased in the ABG|CAI,PE,AST. 
 
 
Figure 7.10: Examples of the implemented personalised ABGs for a patient suspected of 
having a pneumonia infection.  
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CHAPTER 8. DISCUSSION 
The aim of the project was to generate personalised ABGs for hospitalised infectious 
patients. We investigated how to modify an institutional ABG to account for three 
patient specific factors: Nosocomiality, prior exposure to antimicrobials, and AST 
results.  
With regard to the nosocomiality of an infection, we found that when compared to 
CAIs, HAIs were associated with an increased probability of resistance by an OR of 
1.94 (1.87-1.94). It is well known that the nosocomiality should be accounted for 
when selecting antimicrobial therapy (Doron and Davidson, 2011). Our results 
indicate that the effect of PE was even higher than the effect of nosocomiality for 
some antimicrobials. For example, for quinolones the OR for increased resistance 
was 3.35 (2.05-5.47) in GN bacteria isolated from patients exposed to any type of 
antimicrobials within the last month.  
When AST results become available for a limited set of antimicrobials, the effect of 
cross-resistance and cross-susceptibility for all treatments available at a given 
hospital must be considered. We quantified the effect of cross-
susceptibility/resistance between antimicrobials in a crossABG. We developed a 
method which modifies the susceptibility to the untested antimicrobials with respect 
to a patient’s AST results, by using the crossABG. Our results indicate that ORs 
describing cross-susceptibility/resistance can be used to predict the susceptibility to 
untested antimicrobials.  
We developed methods to combine the susceptibility modifications accounting for 
nosocomiality, PE, and AST, respectively. The methods were developed to be 
practical and easily implementable, and during the project we succeeded in 
implementing the methods in an existing software system for antimicrobial 
stewardship (TREAT).  
Future work includes a validation of the method presented in Chapter 5, which was 
used to modify the ABG to prior exposure. The method presented in Chapter 6 should 
likewise be validated by making an attempt to recalculate the susceptibility, while 
including the effect of other AST results and PE. 
In Chapter 2 we took steps to improve the quality of the susceptibilities presented in 
an institutional ABG. AST results from similar species were mapped into pathogen 
groups to decrease the risk of estimating susceptibilities on the basis of a few or zero 
results. The quality of the susceptibilities was further optimised by including AST 
results from a similar institution and by including opinions from experts. It should 
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also be considered whether the crossABG could likewise be improved, in cases of 
missing data, by using statistics from similar antimicrobials.  
When quantifying the effect of prior antimicrobial exposure, we were not able to 
access data on exposure going further back than one month. The time since 
antimicrobial exposure is however a factor that affects the level of increased 
resistance, which may persist for up to 12 months (Costelloe et al., 2010). Studies 
reporting the quantity of antimicrobials prescribed found that longer duration and 
multiple courses were associated with higher rates of resistance (Costelloe et al., 
2010). Hence the duration of prior antimicrobial treatment could also be considered 
as a patient specific factor. 
Another patient specific factor, not addressed in the thesis, is clinically failing 
treatment. If a patient is not responding to a given antimicrobial treatment this could 
indicate that the pathogens causing the infection are resistant to the given treatment. 
In that case, the probability of susceptibility to the treatment should be adjusted and 
likewise for antimicrobials showing cross-resistance to the ineffective antimicrobial. 
Future studies could analyse data from patients with clinically failing treatment, to 
clarify how to generate personalised ABGs accounting for clinically failing 
treatment. These ABGs could be clinically important, when a current treatment fails 
and a new treatment should be selected. 
The personalised ABGs generated in this project could serve as a better prediction of 
antimicrobial susceptibility than traditional institutional ABGs. Thereby the project 
seeks to contribute to patient specific antimicrobial stewardship by supporting 
clinicians in giving targeted personalised therapy and avoid failure of therapy due to 
resistant microbes. 
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Appendix A.  
Modifying the resistance to an 
antimicrobial after PE to the same 
antimicrobial class 
 
We assume that a given pathogen has an ABG presenting a set of N antimicrobials: 
N = {1, …, n, …, N} and a corresponding set of AST results: 𝑨𝑵 = {𝐴1, …, 𝐴𝑛, …, 
𝐴𝑁}, where 𝐴𝑛 is either susceptible (𝑎𝑛) or resistant (¬𝑎𝑛).  
The prior probability of susceptibility to an antimicrobial 𝐴𝑛, is denoted as 𝑃(𝑎𝑛). 
The corresponding probability of resistance to 𝐴𝑛 is denoted as 𝑃(¬𝑎𝑛). Hence 
𝑃(¬𝑎𝑛) = 1 − 𝑃(𝑎𝑛). 
The aim is to calculate the posterior probability 𝑃∗(¬𝑎𝑛) of resistance to 
antimicrobial 𝐴𝑛, given PE to an antimicrobial of the same class. 
The idea was to use an OR for resistance, given PE to the same class of 
antimicrobials, denoted as 𝑂𝑅¬𝑎𝑛|𝑃𝐸=𝑠𝑎𝑚𝑒 .  
First, we define the prior odds 𝑂𝐷¬𝒂𝒏 for resistance to 𝐴𝑛 as: 
𝑂𝐷¬𝑎𝑛 = 𝑃(¬𝑎𝑛)/𝑃(𝑎𝑛) (Eq. 1) 
 
The posterior odds for resistance to An, given PE to the same class of antimicrobials 
is defined as: 
𝑂𝐷¬𝑎𝑛
∗ = 𝑃∗(¬𝑎𝑛)/𝑃
∗(𝑎𝑛) (Eq. 2) 
where 𝑃(𝑎𝑛) is the probability of resistance for patients without PE and 𝑃
∗(𝑎𝑛) is 
the probability of resistance for patient with PE. 
𝑂𝑅¬𝑎𝑛|𝑃𝐸=𝑠𝑎𝑚𝑒  is defined as: 
𝑂𝑅¬𝑎𝑛|𝑃𝐸=𝑠𝑎𝑚𝑒 =
𝑂𝐷¬𝑎𝑛
∗
𝑂𝐷¬𝑎𝑛
=
𝑃∗(¬𝑎𝑛)
𝑃∗(𝑎𝑛)
 ∙
𝑃(𝑎𝑛)
𝑃(¬𝑎𝑛)
  
(Eq. 3) 
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By isolating 𝑂𝐷¬𝑎𝑛
∗  in Eq. 3, we get: 
𝑂𝐷¬𝑎𝑛
∗ = 𝑂𝐷¬𝑎𝑛 ∙  𝑂𝑅¬𝑎𝑛|𝑃𝐸=𝑠𝑎𝑚𝑒   (Eq. 4) 
We assume that 𝑃(𝑎𝑛) is known from the patient’s ABG and that 𝑂𝑅¬𝑎𝑛|𝑃𝐸=𝑠𝑎𝑚𝑒  is 
known from Chapter 4. This allows calculation of  𝑃(¬𝑎𝑛) = 1- 𝑃(𝑎𝑛), 𝑂𝐷¬𝑎𝑛 (Eq. 
1), and 𝑂𝐷¬𝑎𝑛
∗ (Eq. 4), in that order. 
Finally, the posterior probability of resistance, 𝑃∗(¬𝑎𝑛), can then be calculated by 
using the mathematical relationship between odds and probability:  
𝑃∗(¬𝑎𝑛) =  
𝑂𝐷¬𝑎𝑛
∗
1 +  𝑂𝐷¬𝑎𝑛
∗
 
(Eq. 5) 
And if desired also 𝑃∗(𝑎𝑛) as: 
𝑃∗(𝑎𝑛) = 1 − 𝑃
∗(¬𝑎𝑛) 
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Modifying the resistance to an 
antimicrobial after PE to other classes 
of antimicrobials 
 
The question is now how to modify the probability of resistance to antimicrobials 
from other classes. Consider an antimicrobial 𝐵, which is a member of the set of 𝑁 
antimicrobials and belongs to another class than the antimicrobial 𝐴𝑛, to which the 
patient was exposed. The prior probability of susceptibility to antimicrobial B, is 
denoted as 𝑃(𝑏). The corresponding probability of resistance to B is denoted as 
𝑃(¬𝑏). The aim is to calculate the posterior probability 𝑃∗(¬𝑏) after exposure to 𝐴𝑛 
has modified the probability of resistance to antimicrobial 𝐴𝑛 from 𝑃(¬𝑎𝑛) to 
𝑃∗(¬𝑎𝑛).  
Marginalisation of the joint probability of 𝑃(𝐵, 𝐴𝑛) gives: 
𝑃(¬𝑏) = 𝑃(¬𝑏, 𝑎𝑛) +  𝑃(¬𝑏, ¬𝑎𝑛) (Eq. 6) 
By the first probability axiom we have: 
𝑃(¬𝑏) = 𝑃(¬𝑏| 𝑎𝑛) ∙ 𝑃(𝑎𝑛) +  𝑃(¬𝑏|¬𝑎𝑛) ∙ 𝑃(¬𝑎𝑛) (Eq. 7) 
where 𝑃(¬𝑏|𝐴𝑛) is the vector of conditional probabilities of resistance to B given 
the outcome of 𝐴𝑛: 𝑃(¬𝑏|𝑎𝑛) and 𝑃(¬𝑏|¬𝑎𝑛). 
When we learn 𝑃∗(𝑎𝑛) (Eq. 5), our belief in B is revised, such that using Eq. 7 we 
have: 
𝑃∗(¬𝑏) = 𝑃(¬𝑏| 𝑎𝑛) ∙ 𝑃
∗(𝑎𝑛) +  𝑃(¬𝑏|¬𝑎𝑛) ∙ 𝑃
∗(¬𝑎𝑛) (Eq. 8) 
 
where we assume that 𝑃(¬𝑏|𝑎𝑛) and 𝑃(¬𝑏|¬𝑎𝑛) are available from a crossABG. 
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The relation between ORs for 
susceptibility and ORs for resistance 
 
The crossABG contains OR for susceptibility (Chapter 3), while the effect of PE is 
described as ORs for resistance (Chapter 5). This section explains how an OR for 
susceptibility mathematically be converted to an OR for resistance, which is 
convenient, when combining these. 
𝑂𝑅𝑏|𝐴𝑛  is the OR for susceptibility to an antimicrobial B (b), given the susceptibility 
to antimicrobial 𝐴𝑛 (susceptible (𝑎𝑛) or resistant (¬𝑎𝑛)).  
𝑂𝑅¬𝑏|𝐴𝑛  is the OR for resistance to antimicrobial B (¬b), due to PE to antimicrobial 
𝐴𝑛.  
𝑂𝑅𝑏|𝐴𝑛  can be calculated from 𝑂𝑅¬𝑏|𝐴𝑛  and visa versa, as demonstrated below: 
𝑂𝑅¬𝑏|𝐴𝑛   is defined as: 
𝑂𝑅¬𝑏|𝐴𝑛 =
𝑂𝐷¬𝑏|𝐴𝑛
𝑂𝐷¬𝑏
=
𝑃(¬𝑏|𝐴𝑛)
𝑃(𝑏|𝐴𝑛)
 ∙
𝑃(𝑏)
𝑃(¬𝑏)
  (Eq. 9) 
and 𝑂𝑅𝑏|𝐴𝑛   is defined as: 
𝑂𝑅𝑏|𝐴𝑛 =
𝑂𝐷𝑏|𝐴𝑛
𝑂𝐷𝑏
=
𝑃(𝑏|𝐴𝑛)
𝑃(¬𝑏|𝐴𝑛)
 ∙
𝑃(¬𝑏)
𝑃(𝑏)
  (Eq. 10) 
From Eq. 9 we have: 
𝑂𝑅¬𝑏|𝐴𝑛 ∙  
𝑃(𝑏|𝐴𝑛)
𝑃(¬𝑏|𝐴𝑛)
 ∙
𝑃(¬𝑏)
𝑃(𝑏)
= 1  
(Eq. 11) 
 which equals: 
𝑂𝑅¬𝑏|𝐴𝑛 ∙  
𝑂𝐷𝑏|𝐴𝑛
𝑂𝐷𝑏
= 1  
(Eq. 12) 
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Using the definition of 𝑂𝑅𝑏|𝐴𝑛  from Eq. 10, we have: 
𝑂𝑅¬𝑏|𝐴𝑛 ∙  𝑂𝑅𝑏|𝐴𝑛 = 1  
(Eq. 13) 
and hence: 
𝑂𝑅𝑏|𝐴𝑛 =
1
𝑂𝑅¬𝑏|𝐴𝑛
  
 
 
(Eq. 14) 
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